WO2015195695A1 - Procédés, réactifs et cellules pour la biosynthèse de composés - Google Patents

Procédés, réactifs et cellules pour la biosynthèse de composés Download PDF

Info

Publication number
WO2015195695A1
WO2015195695A1 PCT/US2015/036074 US2015036074W WO2015195695A1 WO 2015195695 A1 WO2015195695 A1 WO 2015195695A1 US 2015036074 W US2015036074 W US 2015036074W WO 2015195695 A1 WO2015195695 A1 WO 2015195695A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
activity
coa
ester
seq
Prior art date
Application number
PCT/US2015/036074
Other languages
English (en)
Inventor
Adriana Leonora Botes
Alex van Eck CONRADIE
Ramdane Haddouche
Original Assignee
INVISTA Technologies S.á.r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INVISTA Technologies S.á.r.l. filed Critical INVISTA Technologies S.á.r.l.
Priority to CN201580043260.XA priority Critical patent/CN106795536A/zh
Priority to EP15731806.4A priority patent/EP3155110A1/fr
Priority to BR112016029365A priority patent/BR112016029365A2/pt
Publication of WO2015195695A1 publication Critical patent/WO2015195695A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C07C47/12—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing more than one —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/325—Saturated compounds containing more than one carboxyl group containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/44—Polycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/99—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with other acceptors (1.2.99)
    • C12Y102/99006—Carboxylate reductase (1.2.99.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/15—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen (1.14.15)
    • C12Y114/15001—Camphor 5-monooxygenase (1.14.15.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/15—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen (1.14.15)
    • C12Y114/15003—Alkane 1-monooxygenase (1.14.15.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01018—Beta-alanine-pyruvate transaminase (2.6.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01019—4-Aminobutyrate—2-oxoglutarate transaminase (2.6.1.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01029—Diamine transaminase (2.6.1.29)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01048—5-Aminovalerate transaminase (2.6.1.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01082—Putrescine aminotransferase (2.6.1.82)

Definitions

  • This invention relates to methods for biosynthesizing 5-hydroxypentanoate methyl ester and pentanoic acid pentyl ester using one or more isolated enzymes such as a fatty acid O-methyltransferase, an alcohol O-acetyltransf erase, and a monooxygenase, and to recombinant host cells expressing one or more such enzymes.
  • isolated enzymes such as a fatty acid O-methyltransferase, an alcohol O-acetyltransf erase, and a monooxygenase
  • This invention also relates to methods for enzymatically converting 5-hydroxypentanoate methyl ester and pentanoic acid pentyl ester to 5-hydroxypentanoate and 1,5-pentanediol using one or more enzymes such as an a monooxygenase, a demethylase, or an esterase, and recombinant hosts expressing one or more such enzymes.
  • one or more enzymes such as an a monooxygenase, a demethylase, or an esterase
  • this invention relates to enzymatically converting 5-hydroxypentanoate and/or 1,5-pentanediol to glutaric acid, 5-aminopentanoic acid, cadaverine or 1,5-pentanediol (hereafter "C5 building blocks) and recombinant hosts producing such C5 building blocks.
  • Nylons are polyamides which are generally synthesized by the condensation polymerization of a diamine with a dicarboxylic acid. Similarly, Nylons may be produced by the condensation polymerization of lactams.
  • a ubiquitous nylon is Nylon 6,6, which is produced by condensation polymerization of hexamethylenediamine (HMD) and adipic acid.
  • Nylon 6 can be produced by a ring opening polymerization of caprolactam (Anton & Baird, Polyamides Fibers, Encyclopedia of Polymer Science and Technology, 2001).
  • Nylon 5 and Nylon 5,5 represent novel polyamides with value-added
  • Nylon 5 is produced by
  • Biocatalysis is the use of biological catalysts, such as enzymes, to perform biochemical transformations of organic compounds.
  • the dicarboxylic acid glutaric acid is converted efficiently as a carbon source by a number of bacteria and yeasts via ⁇ -oxidation into central metabolites.
  • Decarboxylation of Coenzyme A (CoA) activated glutarate to crotonyl-CoA facilitates further catabolism via ⁇ -oxidation.
  • the optimality principle states that microorganisms regulate their biochemical networks to support maximum biomass growth. Beyond the need for expressing heterologous pathways in a host organism, directing carbon flux towards C5 building blocks that serve as carbon sources rather than as biomass growth constituents, contradicts the optimality principle. For example, transferring the 1-butanol pathway from Clostridium species into other production strains has often fallen short by an order of magnitude compared to the production performance of native producers (Shen et ah, Appl. Environ. Microbiol, 2011, 77(9):2905 - 2915).
  • the efficient synthesis of the seven carbon aliphatic backbone precursor is a key consideration in synthesizing one or more C5 building blocks prior to forming terminal functional groups, such as carboxyl, amine or hydroxyl groups, on the C5 aliphatic backbone.
  • Glutaric acid and glutarate 5-hydroxypentanoic acid and 5-hydroxypentanoate, and 5- aminopentanoic and 5-aminopentanoate are used interchangeably herein to refer to the relevant compound in any of its neutral or ionized forms, including any salt forms thereof. It is understood by those skilled in the art that the specific form will depend on pH.
  • carboxylic acid groups including, but not limited to, organic monoacids, hydroxyacids, aminoacids, and dicarboxylic acids
  • carboxylic acid groups include, but not limited to, organic monoacids, hydroxyacids, aminoacids, and dicarboxylic acids
  • a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base.
  • Acceptable organic bases include, but are not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
  • Acceptable inorganic bases include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
  • a salt of the present invention is isolated as a salt or converted to the free acid by reducing the pH to below the pKa, through addition of acid or treatment with an acidic ion exchange resin.
  • amine groups including, but not limited to, organic amines, aminoacids, and diamines
  • ionic salt form for example, by addition of an acidic proton to the amine to form the ammonium salt, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids including, but not limited to, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethaned
  • benzenesulfonic acid 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-l- carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like.
  • Acceptable inorganic bases include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
  • a salt of the present invention is isolated as a salt or converted to the free amine by raising the pH to above the pKb through addition of base or treatment with a basic ion exchange resin.
  • Acceptable inorganic bases include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like, or 2) when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base.
  • Acceptable organic bases include, but are not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N- methylglucamine, and the like.
  • Acceptable inorganic bases include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
  • a salt can of the present invention is isolated as a salt or converted to the free acid by reducing the pH to below the pKa through addition of acid or treatment with an acidic ion exchange resin.
  • Pathways, metabolic engineering and cultivation strategies described herein can rely on producing pentanoate methyl ester from pentanoate using, for example, a fatty acid O-methyltransf erase and producing 5-hydroxypentanoate methyl ester from pentanoate methyl ester using, for example, a monooxygenase.
  • 5-hydroxypentanoate can be produced from 5-hydroxypentanoate methyl ester using, for example, a demethylase or an esterase.
  • Pathways, metabolic engineering and cultivation strategies described herein also can rely on producing pentanoic acid pentyl ester using, for example, an alcohol O- acetyltransf erase and producing 5-hydroxypentanoic acid pentyl ester, 5- hydroxypentanoic acid 5-hydroxypentyl ester and/or pentanoic acid 5-hydroxypentyl ester from pentanoic acid pentyl ester using, for example, a monooxygenase.
  • 5- hydroxypentanoate can be produced from 5-hydroxypentanoic acid pentyl ester and/or 5- hydroxypentanoic acid 5-hydroxypentyl ester using, for example, an esterase.
  • 1,5- pentanediol can be produced from pentanoic acid 5-hydroxypentyl ester and/or 5- hydroxypentanoic acid 5-hydroxypentyl ester using, for example, an esterase.
  • CoA-dependent elongation enzymes or homo logs associated with the carbon storage pathways from polyhydroxyalkano ate accumulating bacteria are useful for producing precursor molecules. See, e.g., FIGs. 1-2.
  • the inventors discovered surprisingly that appropriate non-natural pathways, feedstocks, host microorganisms, attenuation strategies to the host's biochemical network and cultivation strategies may be combined to efficiently produce one or more C5 building blocks.
  • the C5 aliphatic backbone for conversion to a C5 building block can be formed from acetyl-CoA and propanoyl-CoA via two cycles of CoA- dependent carbon chain elongation using either NADH or NADPH dependent enzymes. See FIG. 1 and FIG. 2.
  • an enzyme in the CoA-dependent carbon chain elongation pathway generating the C5 aliphatic backbone purposefully contains irreversible enzymatic steps.
  • the terminal carboxyl groups can be enzymatically formed using a thioesterase, an aldehyde dehydrogenase, a 7-oxoheptanoate
  • dehydrogenase a 6-oxohexanoate dehydrogenase, a 5-oxopentanoate dehydrogenase or a monooxygenase. See FIG. 3 and FIG. 4.
  • the terminal amine groups can be enzymatically formed using a ⁇ -transaminase or a deacetylase. See FIG. 5 and FIG. 6.
  • the terminal hydroxyl group can be enzymatically formed using a monooxygenase, an esterase, or an alcohol dehydrogenase. See FIG. 3, FIG. 7 and FIG. 8.
  • a monooxygenase e.g., in combination with an oxidoreductase and/or ferredoxin
  • an alcohol dehydrogenase can enzymatically form a hydroxyl group.
  • the monooxygenase can have at least 70% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 14-16 or 28-29.
  • An esterase can have at least 70% identity to the amino acid sequence set forth in SEQ ID NO: 27.
  • a ⁇ -transaminase or a deacetylase can enzymatically form an amine group.
  • the ⁇ -transaminase can have at least 70% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs. 8 - 13.
  • a thioesterase, an aldehyde dehydrogenase, a 7-oxoheptanoate dehydrogenase, a 5-oxopentanoate dehydrogenase, or a 6-oxohexanoate dehydrogenase can enzymatically form a terminal carboxyl group.
  • the thioesterase can have at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 33, and/or SEQ ID NO: 34.
  • a carboxylate reductase (e.g., in combination with a phosphopantetheinyl transferase) can form a terminal aldehyde group as an intermediate in forming the product.
  • the carboxylate reductase can have at least 70% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOs: 2 - 7.
  • Any of the methods can be performed in a recombinant host by fermentation.
  • the host can be subjected to a cultivation strategy under aerobic, anaerobic, or micro- aerobic cultivation conditions.
  • the host can be cultured under conditions of nutrient limitation such as phosphate, oxygen or nitrogen limitation.
  • the host can be retained using a ceramic membrane to maintain a high cell density during fermentation.
  • the host's tolerance to high concentrations of a C5 building block can be improved through continuous cultivation in a selective
  • the principal carbon source fed to the fermentation can derive from biological or non-biological feedstocks.
  • the biological feedstock is, includes, or derives from, monosaccharides, disaccharides, lignocellulose, hemicellulose, cellulose, lignin, levulinic acid and formic acid, triglycerides, glycerol, fatty acids, agricultural waste, condensed distillers' solubles, or municipal waste.
  • the non-biological feedstock is or derives from natural gas, syngas, CO2/H2, methanol, ethanol, benzoate, non-volatile residue (NVR) or a caustic wash waste stream from cyclohexane oxidation processes, or a terephthalic acid/isophthalic acid mixture waste stream.
  • This document also features a recombinant host that includes at least one exogenous nucleic acid encoding a fatty acid O-methyltransferase and a monooxygenase, and produce 5-hydroxypentanoate methyl ester.
  • a host further can include a demethylase or esterase and further produce 5-hydroxypentanoate.
  • Such hosts further can include (i) a ⁇ -ketothiolase or an acetyl-CoA carboxylase and a ⁇ -ketoacyl- facpj synthase, (ii) a 3-hydroxyacyl-CoA dehydrogenase or a 3-oxoacyl-CoA reductase, (iii) an enoyl-CoA hydratase, and (iv) a trans-2-enoyl-CoA reductase.
  • the hosts also further can include one or more of a thioesterase, an aldehyde dehydrogenase, or a butanal dehydrogenase.
  • This document also features a recombinant host that includes at least one exogenous nucleic acid encoding an alcohol O-acetyltransf erase and produce pentanoic acid pentyl ester.
  • a host further can include a monooxygenase and an esterase and further produce 5-hydroxypentanoate and/or 1,5-pentanediol.
  • Such hosts further can include (i) a ⁇ -ketothiolase or an acetyl-CoA carboxylase and a ⁇ -ketoacyl- facpj synthase, (ii) a 3-hydroxyacyl-CoA dehydrogenase or a 3-oxoacyl-CoA reductase, (iii) an enoyl-CoA hydratase, and (iv) a trans-2-enoyl-CoA reductase.
  • the hosts also further can include one or more of a thioesterase, a carboxylate reductase, an aldehyde
  • dehydrogenase a butanal or acetaldehyde dehydrogenase, or an alcohol dehydrogenase.
  • a recombinant host producing 5-hydroxypentanoate further can include one or more of a monooxygenase, an alcohol dehydrogenase, an aldehyde dehydrogenase, a 6- hydroxyhexanoate dehydrogenase, a 5-hydroxypentanoate dehydrogenase, a 4- hydroxybutyrate dehydrogenase, a 7-oxoheptanoate dehydrogenase, a 6-oxohexanoate dehydrogenase, or a 5-oxopentanoate dehydrogenase, the host further producing glutaric acid or glutarate semialdehyde.
  • a recombinant host producing 5-hydroxypentanoate further can include one or more of a monooxygenase, a transaminase, a 6-hydroxyhexanoate dehydrogenase, a 5- hydroxypentanoate dehydrogenase, a 4-hydroxybutyrate dehydrogenase, and an alcohol dehydrogenase, wherein the host further produces 5-aminopentanoate.
  • a recombinant host producing 5-hydroxypentanoate or 5-aminopentanoate further can include one or more of a carboxylate reductase, a ⁇ -transaminase, a deacetylase, a N-acetyl transferase, or an alcohol dehydrogenase, the host further producing cadaverine.
  • a recombinant host producing 5-hydroxypentanoate further can include a carboxylate reductase or an alcohol dehydrogenase, wherein the host further produces 1,5-pentanediol.
  • the recombinant host can be a prokaryote, e.g., from the genus Escherichia such as Escherichia coli; from the genus Clostridia such as Clostridium ljungdahlii, Clostridium autoethanogenum or Clostridium kluyveri; from the genus Cory b acteria such as Corymb acterium glutamicum; from the genus Cupriavidus such as Cupriavidus necator or Cupriavidus metallidurans; from the genus Pseudomonas such as
  • Pseudomonas fluorescens Pseudomonas putida or Pseudomonas oleavorans
  • from the genus Delftia acidovorans from the genus Bacillus such as Bacillus subtillis
  • from the genes Lactobacillus such as Lactobacillus delbrueckii
  • from the genus Lactococcus such as Lactococcus lactis or from the genus Rhodococcus such as Rhodococcus equi.
  • the recombinant host can be a eukaryote, e.g., a eukaryote from the genus Aspergillus such as Aspergillus niger; from the genus Saccharomyces such as
  • Saccharomyces cerevisiae from the genus Pichia such as Pichia pastoris; from the genus Yarrowia such as Yarrowia lipolytica, from the genus Issatchenkia such as Issathenkia orientalis, from the genus Debaryomyces such as Debaryomyces hansenii, from the genus Arxula such as Arxula adenoinivorans, or from the genus Kluyveromyces such as Kluyveromyces lactis.
  • the host's endogenous biochemical network is attenuated or augmented to (1) ensure the intracellular availability of acetyl-CoA and propanoyl- CoA, (2) create a cofactor, i.e. NADH or NADPH, imbalance that may be balanced via the formation of a C5 building block, (3) prevent degradation of central metabolites, central precursors leading to and including C5 building blocks and (4) ensure efficient efflux from the cell.
  • acetyl-CoA and propanoyl- CoA (2) create a cofactor, i.e. NADH or NADPH, imbalance that may be balanced via the formation of a C5 building block, (3) prevent degradation of central metabolites, central precursors leading to and including C5 building blocks and (4) ensure efficient efflux from the cell.
  • any of the recombinant hosts described herein further can include one or more of the following attenuated enzymes: polyhydroxyalkanoate synthase, an acetyl-CoA thioesterase, a propanoyl-CoA thioesterase, a methylcitrate synthase, an acetyl-CoA specific ⁇ -ketothiolase, a phosphotransacetylase forming acetate, an acetate kinase, a lactate dehydrogenase, a menaquinol-fumarate oxidoreductase, a 2-oxoacid
  • decarboxylase producing isobutanol, an alcohol dehydrogenase forming ethanol, a triose phosphate isomerase, a pyruvate decarboxylase, a glucose-6-phosphate isomerase, a transhydrogenase dissipating the cofactor imbalance, a glutamate dehydrogenase specific for the co-factor for which an imbalance is created, a NADH/NADPH-utilizing glutamate dehydrogenase, a pimeloyl-CoA dehydrogenase; an acyl-CoA dehydrogenase accepting C5 building blocks and central precursors as substrates; a glutaryl-CoA dehydrogenase; or a pimeloyl-CoA synthetase.
  • any of the recombinant hosts described herein further can overexpress one or more genes encoding: an acetyl-CoA synthetase, a 6-phosphogluconate dehydrogenase; a transketolase; a feedback resistant threonine deaminase; a puridine nucleotide transhydrogenase; a formate dehydrogenase; a glyceraldehydeSP-dehydrogenase; a malic enzyme; a glucose-6-phosphate dehydrogenase; a fructose 1,6 diphosphatase; a propionyl-CoA synthetase; a L-alanine dehydrogenase; a L-glutamate dehydrogenase; a L-glutamine synthetase; a / wme transporter; a dicarboxylate transporter; and/or a multidrug transporter.
  • the polypeptide having atty acid O- methyltransf erase activity is classified under EC 2.1.1.15.
  • the polypeptide having fatty acid O-methyltransf erase activity can have at least 70% sequence identity to an amino acid sequence set forth in SEQ ID NO:23, SEQ ID NO:24, or SEQ ID NO:25.
  • the monooxygenase is classified under EC 1.14.14.- or EC 1.14.15.-.
  • the monooxygenase can have at least 70% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO:28 and/or SEQ ID NO:29.
  • the C4-9 carboxylic acid can be enzymatically produced from a C4-9 alkanoyl-CoA.
  • a polypeptide having thioesterase activity can enzymatically produce the C4-9 carboxylic acid from the C4-9 alkanoyl-CoA.
  • the thioesterase can have at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: l, SEQ ID NO: 33, and/or SEQ ID NO: 34.
  • a polypeptide having butanal dehydrogenase activity and a polypeptide having aldehyde dehydrogenase activity enzymatically produce the C4-9 carboxylic acid from C4-9 alkanoyl-Co A.
  • the alcohol O-acetyltransf erase can have at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: 26.
  • the alkyl) ester using a polypeptide having monooxygenase activity can be classified under EC 1.14.14.- or EC 1.14.15.-.
  • the method further can include enzymatically converting the (C4-9 hydroxyalkyl) ester or (C4-9 hydroxyalkyl)- alkyl) ester to a C4-9 hydroxyalkanoate.
  • this document features a method for producing a bioderived 5- carbon compound.
  • the method for producing a bioderived 5-carbon compound can include culturing or growing a recombinant host as described herein under conditions and for a sufficient period of time to produce the bioderived 5-carbon compound, wherein, optionally, the bioderived 5-carbon compound is selected from the group consisting of glutaric acid, glutarate semialdehyde, 5-aminopentanoate acid, 5-hydroxypentanoate, pentamethylenediamme, 1,5-pentanediol, and combinations thereof.
  • composition comprising a bioderived 5- carbon compound as described herein and a compound other than the bioderived 5- carbon compound, wherein the bioderived 5-carbon compound is selected from the group consisting of glutaric acid, glutarate semialdehyde, 5-aminopentanoate acid, 5- hydro xypentanoate, pentamethylenediamme, 1,5-pentanediol, and combinations thereof.
  • the bioderived 5-carbon compound is a cellular portion of a host cell or an organism.
  • This document also features a biobased polymer comprising the bioderived glutaric acid, glutarate semialdehyde, 5-aminopentanoate acid, 5-hydroxypentanoate, pentamethylenediamme, 1,5-pentanediol, and combinations thereof.
  • This document also features a biobased resin comprising the bioderived glutaric acid, glutarate semialdehyde, 5-aminopentanoate acid, 5-hydroxypentanoate,
  • this document features a process for producing a biobased polymer that includes chemically reacting the bioderived glutaric acid, glutarate semialdehyde, 5-aminopentanoate acid, 5-hydroxypentanoate, pentamethylenediamme, 1,5-pentanediol, and combinations thereof with itself or another compound in a polymer producing reaction.
  • this document features a process for producing a biobased resin that includes chemically reacting the bioderived glutaric acid, glutarate semialdehyde, 5- aminopentanoate acid, 5-hydroxypentanoate, pentamethylenediamme, 1,5-pentanediol, and combinations thereof with itself or another compound in a resin producing reaction.
  • this document provides a bio-derived product, bio-based product or fermentation-derived product, wherein said product comprises: (i) a composition comprising at least one bio-derived, bio-based or fermentation- derived compound provided herein or in any one of FIGs 1-9, or any combination thereof;
  • a bio-derived, bio-based or fermentation-derived resin comprising the bio- derived, bio-based or fermentation-derived compound or bio-derived, bio-based or fermentation-derived composition of (i) or any combination thereof or the bio-derived, bio-based or fermentation-derived polymer of (ii) or any combination thereof;
  • a bio-derived, bio-based or fermentation-derived formulation comprising the bio-derived, bio-based or fermentation-derived composition of (i), bio-derived, bio- based or fermentation-derived compound of (i), bio-derived, bio-based or fermentation-derived polymer of (ii), bio-derived, bio-based or fermentation-derived resin of (iii), or bio-derived, bio-based or fermentation-derived molded substance of (iv), or any combination thereof; or
  • a bio-derived, bio-based or fermentation-derived semi-solid or a non-semi- solid stream comprising the bio-derived, bio-based or fermentation-derived composition of (i), bio-derived, bio-based or fermentation-derived compound of (i), bio-derived, bio- based or fermentation-derived polymer of (ii), bio-derived, bio-based or fermentation-derived resin of (iii), bio-derived, bio-based or fermentation-derived formulation of (v), or bio-derived, bio-based or fermentation-derived molded substance of (iv), or any combination thereof.
  • biochemical network comprising at least one exogenous nucleic acid encoding a polypeptide having (i) fatty acid O-methyltransf erase activity or alcohol O-acetyltransf erase activity, (ii) monooxygenase activity, and (iii) esterase or demethylase activity. Also, described herein is a biochemical network comprising at least one exogenous nucleic acid encoding a polypeptide having fatty acid O-methyltransf erase activity and a polypeptide having monooxygenase activty, wherein the biochemical network enzymatically produces 5-hydroxypentanoate methyl ester.
  • the biochemical network can further include a polypeptide having demethylase activity or a polypeptide having esterase activity, wherein the polypeptide having demethylase activity or a polypeptide having esterase activity enzymatically produce 5-hydroxypentanoate.
  • the biochemical network can further include at least one exogenous nucleic acid encoding a polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl-facpj synthase activity, a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity or a polypeptide having 3-oxoacyl-CoA reductase activity, a polypeptide having enoyl-CoA hydratase activity, and a polypeptide having trans-2-enoyl-CoA reductase activity, wherein the polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl- [acp] synthase activity, a polypeptide having 3- hydroxyacyl-CoA dehydrogenase activity or
  • the biochemical network can further one or more of an exogenous polypeptide having thioesterase activity, a polypeptide having aldehyde dehydrogenase activity, or a polypeptide having butanal dehydrogenase activity, wherein the polypeptide having thioesterase activity, a polypeptide having aldehyde dehydrogenase activity or a polypeptide having butanal dehydrogenase activity enzymatically produce pentanoate as a C5 precursor molecule.
  • biochemical network comprising at least one exogenous nucleic acid encoding a polypeptide having alcohol O-acetyltransf erase activity and a polypeptide having monooxygenase activity, wherein the biochemical network produces pentanoic acid pentyl ester.
  • the biochemical network can further include an esterase, wherein the esterase enzymatically converts pentanoic acid pentyl ester to 5-hydroxypentanoate and/or 1,5-pentanediol.
  • the biochemical network can further include at least one exogenous nucleic acid encoding a polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl-facpj synthase activity, a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity or a polypeptide having 3-oxoacyl-CoA reductase activity, a polypeptide having enoyl-CoA hydratase activity, and a polypeptide having trans-2-enoyl-CoA reductase activity, wherein the polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl- [acp] synthase activity, a polypeptide having 3- hydroxyacyl-CoA dehydrogenase activity or
  • the biochemical network can further include one or more of an exogenous a polypeptide having aldehyde dehydrogenase activity a polypeptide having alcohol dehydrogenase activity, a polypeptide having butanal dehydrogenase activity, a polypeptide having carboxylate reductase activity or a polypeptide having thioesterase activity, wherein the polypeptide having aldehyde dehydrogenase activity, a polypeptide having alcohol dehydrogenase activity, a polypeptide having butanal dehydrogenase activity, a polypeptide having carboxylate reductase activity or a polypeptide having thioesterase activity enzymatically produce pentanol as a C5 precursor molecule.
  • a biochemical network producing 5-hydroxypentanoate can further include one or more of a polypeptide having monooxygenase activity, a polypeptide having alcohol dehydrogenase activity, a polypeptide having aldehyde dehydrogenase activity, a polypeptide having 7-oxohexanoate dehydrogenase activity, a polypeptide having 6- oxohexanoate dehydrogenase activity, a polypeptide having 5-hydroxypentanoate dehydrogenase activity, a polypeptide having 4-hydroxybutyrate dehydrogenase activity or a polypeptide having 6-hydroxyhexanoate dehydrogenase activity, wherein the polypeptide having monooxygenase activity, a polypeptide having alcohol dehydrogenase activity, a polypeptide having aldehyde dehydrogenase activity, a polypeptide having 7-oxohexanoate dehydrogenase activity, a polypeptide
  • a biochemical network producing 5-hydroxypentanoate can further include one or more of a polypeptide having ⁇ -transaminase activity, a polypeptide having 6- hydroxyhexanoate dehydrogenase activity, a polypeptide having 5-hydroxybutanoate dehydrogenase activity, a polypeptide having 4-hydroxybutyrate dehydrogenase activity and a polypeptide having alcohol dehydrogenase activity, wherein the polypeptide having ⁇ -transaminase activity, a polypeptide having 6-hydroxyhexanoate
  • dehydrogenase activity a polypeptide having 5-hydroxybutanoate dehydrogenase activity, a polypeptide having 4-hydroxybutyrate dehydrogenase activity and a polypeptide having alcohol dehydrogenase activity enzymatically convert 5- hydroxypentanoate to 5-aminopentanoate.
  • a biochemical network producing 5-aminopentanoate, 5-hydroxypentanoate, glutarate semialdehyde, or 1,5-pentanediol can further include one or more of a polypeptide having carboxylate reductase activity, a polypeptide having ⁇ -transaminase activity, a polypeptide having deacetylase activity a polypeptide having N-acetyl transferase activity, or a polypeptide having alcohol dehydrogenase activity, wherein the a polypeptide having carboxylate reductase activity, a polypeptide having ⁇ - transaminase activity, a polypeptide having deacetylase activity a polypeptide having N- acetyl transferase activity, or a polypeptide having alcohol dehydrogenase activity, enzymatically convert 5-aminopentanoate, 5-hydroxypentanoate, glutarate semialdehyde, or 1,5-pentanedi
  • a biochemical network producing 5-hydroxypentanoate can further include one or more of a polypeptide having carboxylate reductase activity and a polypeptide having alcohol dehydrogenase activity, wherein the polypeptide having carboxylate reductase activity and a polypeptide having alcohol dehydrogenase activity enzymatically convert 5-hydroxypentanoate to 1,5-pentanediol.
  • a means for obtaining 5-hydroxypentanoate using (i) a polypeptide having fatty acid O-methyltransf erase activity and a polypeptide having monooxygenase activity and (ii) a polypeptide having demethylase activity or a polypeptide having esterase activity.
  • the means can further include means for converting 5-hydroxypentanoate to at least one of glutaric acid, 5-aminopentanoate, cadaverine, 5- hydroxypentanoate, and 1,5-pentanediol.
  • the means can include a polypeptide having aldehyde dehydrogenase activity, a polypeptide having 7-oxohexanoate dehydrogenase activity, a polypeptide having 6-oxohexanoate dehydrogenase activity, a polypeptide having 5-hydroxypentanoate dehydrogenase activity, a polypeptide having 4- hydroxybutyrate dehydrogenase activity or a polypeptide having 6-hydroxyhexanoate dehydrogenase activity.
  • the means can further include means for converting 5-hydroxypentanoate to at least one of glutaric acid, 5-aminopentanoate, cadaverine, 5- hydroxypentanoate, and 1,5-pentanediol.
  • the means can include a polypeptide having aldehyde dehydrogenase activity, a polypeptide having 7-oxohexanoate dehydrogenase activity, a polypeptide having 6-oxohexanoate dehydrogenase activity, a polypeptide having 5-hydroxypentanoate dehydrogenase activity, a polypeptide having 4- hydroxybutyrate dehydrogenase activity or a polypeptide having 6-hydroxyhexanoate dehydrogenase activity.
  • Also described herein is (i) a step for obtaining 5-hydroxypentanoate using a polypeptide having alcohol O-acetyltransf erase, a polypeptide having monooxygenase activity, and a polypeptide having demethylase activity or a polypeptide having esterase activity, and (ii) a step for obtaining glutaric acid, 5-aminopentanoate, glutarate semialdehyde 1,5-pentanediol, or cadaverine using a polypeptide having carboxylate reductase activity, a polypeptide having alcohol dehydrogenase activity, a polypeptide having ⁇ -transaminase activity, a polypeptide having deacetylase activity a polypeptide having N-acetyl transferase activity, a polypeptide having 6-hydroxyhexanoate dehydrogenase activity, a polypeptide having 5-hydroxybutanoate dehydrogenase activity, a polypeptide having 4-
  • this document features a composition
  • a composition comprising 5- hydroxypentanoate and a polypeptide having alcohol O-acetyltransf erase, a polypeptide having monooxygenase activity, and a polypeptide having demethylase activity or a polypeptide having esterase activity complex.
  • the composition can be cellular.
  • the composition can further include a polypeptide having carboxylate reductase activity, a polypeptide having alcohol dehydrogenase activity, a polypeptide having ⁇ - transaminase activity, a polypeptide having deacetylase activity a polypeptide having N- acetyl transferase activity, a polypeptide having 6-hydroxyhexanoate dehydrogenase activity, a polypeptide having 5-hydroxybutanoate dehydrogenase activity, a polypeptide having 4-hydroxybutyrate dehydrogenase activity, a polypeptide having aldehyde dehydrogenase activity, a polypeptide having 7-oxohexanoate dehydrogenase activity, a polypeptide having 6-oxohexanoate dehydrogenase activity, a polypeptide having 5- hydroxypentanoate dehydrogenase activity, a polypeptide having 4-hydroxybutyrate dehydrogenase activity or a poly
  • the reactions of the pathways described herein can be performed in one or more cell (e.g., host cell) strains (a) naturally expressing one or more relevant enzymes, (b) genetically engineered to express one or more relevant enzymes, or (c) naturally expressing one or more relevant enzymes and genetically engineered to express one or more relevant enzymes.
  • relevant enzymes can be extracted from of the above types of host cells and used in a purified or semi-purified form. Extracted enzymes can optionally be immobilized to the floors and/or walls of appropriate reaction vessels.
  • extracts include lysates (e.g. cell lysates) that can be used as sources of relevant enzymes.
  • all the steps can be performed in cells (e.g., host cells), all the steps can be performed using extracted enzymes, or some of the steps can be performed in cells and others can be performed using extracted enzymes.
  • FIG. 1 is a schematic of exemplary biochemical pathways leading to pentanoyl- Co A using NADH-dependent enzymes and acetyl-Co A and propanoyl-Co A as central metabolites.
  • FIG. 2 is a schematic of exemplary biochemical pathways leading to pentanoyl- CoA using NADPH-dependent enzymes and with acetyl-CoA and propanoyl-CoA as central metabolites.
  • FIG. 3 is a schematic of exemplary biochemical pathways leading to pentanoate and pentanol using pentanoyl-CoA as a central precursor.
  • FIG. 4 is a schematic of an exemplary biochemical pathway leading to glutaric acid using 5-hydroxypentanoate as a central precursor.
  • FIG. 5 is a schematic of an exemplary biochemical pathway leading to 5- aminopentanoate using 5-hydroxypentanoate as a central precursor.
  • FIG. 6 is a schematic of exemplary biochemical pathways leading to cadaverine using 5-aminopentanoate, 5-hydroxypentanoate, glutarate semialdehyde (also known as 5-oxopentanoic acid), or 1,5-pentanediol as a central precursor.
  • FIG. 7 is a schematic of exemplary biochemical pathways leading to 5- hydroxypentanoate via ester intermediates using pentanoate or pentanoyl-CoA.
  • FIG. 7 also contains an exemplary biochemical pathway leading to 5-hydroxypentanoate using 1,5-pentanediol as a central precursor.
  • FIG. 8 is a schematic of exemplary biochemical pathways leading to 1 ,5 pentanediol using 5-hydroxypentanoate or pentanoyl-CoA as a central precursor.
  • FIG. 9 is a schematic of exemplary biochemical pathways leading to propanoyl- CoA from central metabolites.
  • FIG. 10 contains the amino acid sequences of an Escherichia coli thioesterase encoded by tesB (see GenBank Accession No. AAA24665.1, SEQ ID NO: 1), a
  • Genbank Accession No. ABK71854.1 SEQ ID NO: 3
  • a Segniliparus rugosus carboxylate reductase see Genbank Accession No. EFV11917.1 , SEQ ID NO: 4
  • Mycobacterium smegmatis carboxylate reductase see Genbank Accession No.
  • a Segniliparus rotundus carboxylate reductase see Genbank Accession No. ADG98140.1, SEQ ID NO: 7
  • a segmentniliparus rotundus carboxylate reductase see Genbank Accession No. ADG98140.1, SEQ ID NO: 7
  • a segmentniliparus rotundus carboxylate reductase see Genbank Accession No. ADG98140.1, SEQ ID NO: 7
  • Chromobacterium violaceum co-transaminase see Genbank Accession No. AAQ59697.1
  • SEQ ID NO: 8 a Pseudomonas aeruginosa co-transaminase (see Genbank Accession No. AAG08191.1, SEQ ID NO: 9), a Pseudomonas syringae co-transaminase (see Genbank Accession No. AAY39893.1, SEQ ID NO: 10), a Rhodobacter sphaeroides co- transaminase (see Genbank Accession No. ABA81135.1, SEQ ID NO: 11), an
  • Escherichia coli co-transaminase see Genbank Accession No. AAA57874.1, SEQ ID NO: 12
  • a Vibrio fluvialis co-transaminase See Genbank Accession No. AEA39183.1, SEQ ID NO: 13
  • a Polaromonas sp. JS666 monooxygenase see Genbank Accession No. ABE47160.1, SEQ ID NO: 14
  • Mycobacterium sp. HXN-1500 monooxygenase see Genbank Accession No. CAH04396.1, SEQ ID NO: 15
  • austroafricanum monooxygenase see Genbank Accession No. ACJ06772.1, SEQ ID NO: 16
  • a Polaromonas sp. JS666 oxidoreductase see Genbank Accession No.
  • BAC59257.1 SEQ ID NOs: 31 and 32, respectively
  • a Lactobacillus brevis thioesterase GenBank Accession No. ABJ63754.1, SEQ ID NO:33
  • a Lactobacillus plantarum thioesterase GenBank Accession No. CCC58182.1, SEQ ID NO:34.
  • FIG. 11 is a bar graph of the change in absorbance at 340 nm after 20 min, which is a measure of the consumption of NADPH and activity of carboxylate reductases for converting pentanoic acid to pentanal relative to the empty vector control.
  • FIG. 12 is a bar graph summarizing the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and activity of five carboxylate reductase preparations in enzyme only controls (no substrate).
  • FIG. 13 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity of six co-transaminase preparations for converting 5-aminopentanol to 5-oxopentanol relative to the empty vector control.
  • FIG. 14 is a bar graph of the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and the activity of five carboxylate reductase preparations for converting 5-hydroxypentanoate to 5-hydroxypentanal relative to the empty vector control.
  • FIG. 15 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity of five co-transaminase preparations for converting N5 -acetyl- 1, 5 -diaminopentane to N5-acetyl-5-aminopentanal relative to the empty vector control.
  • FIG. 16 is a bar graph of the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and activity of a carboxylate reductase preparation for converting glutarate semialdehyde to pentanedial relative to the empty vector control.
  • FIG. 17 is a bar graph summarizing the percent conversion of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity of the enzyme only controls (no substrate).
  • FIG. 18 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity of one co-transaminase preparation for converting 5-aminopentanoate to glutarate semialdehyde relative to the empty vector control.
  • FIG. 19 is a bar graph of the percent conversion after 4 hours of L-alanine to pyruvate (mol/mol) as a measure of the co-transaminase activity of one co-transaminase preparation for converting glutarate semialdehyde to 5-aminopentanoate relative to the empty vector control.
  • FIG. 20 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity of four co-transaminase preparations for converting cadaverine to 5-aminopentanal relative to the empty vector control.
  • central precursor is used to denote any metabolite in any metabolic pathway shown herein leading to the synthesis of a C5 building block.
  • central metabolite is used herein to denote a metabolite that is produced in all microorganisms to support growth.
  • Host microorganisms described herein can include endogenous pathways that can be manipulated such that one or more C5 building blocks or central precursors thereof can be produced.
  • the host microorganism naturally expresses all of the enzymes catalyzing the reactions within the pathway.
  • a host microorganism containing an engineered pathway does not naturally express all of the enzymes catalyzing the reactions within the pathway but has been engineered such that all of the enzymes within the pathway are expressed in the host.
  • exogenous refers to a nucleic acid that does not occur in (and cannot be obtained from) a cell of that particular type as it is found in nature or a protein encoded by such a nucleic acid.
  • a non-naturally-occurring nucleic acid is considered to be exogenous to a host once in the host. It is important to note that non-naturally-occurring nucleic acids can contain nucleic acid subsequences or fragments of nucleic acid sequences that are found in nature provided the nucleic acid as a whole does not exist in nature.
  • a nucleic acid molecule containing a genomic DNA sequence within an expression vector is non-naturally-occurring nucleic acid, and thus is exogenous to a host cell once introduced into the host, since that nucleic acid molecule as a whole (genomic DNA plus vector DNA) does not exist in nature.
  • any vector, autonomously replicating plasmid, or virus e.g., retrovirus, adenovirus, or herpes virus
  • genomic DNA fragments produced by PCR or restriction endonuc lease treatment as well as cDNAs are considered to be non-naturally-occurring nucleic acid since they exist as separate molecules not found in nature. It also follows that any nucleic acid containing a promoter sequence and polypeptide-encoding sequence (e.g., cDNA or genomic DNA) in an arrangement not found in nature is non-naturally- occurring nucleic acid.
  • a nucleic acid that is naturally-occurring can be exogenous to a particular host microorganism. For example, an entire chromosome isolated from a cell of yeast x is an exogenous nucleic acid with respect to a cell of yeast y once that chromosome is introduced into a cell of yeast y.
  • endogenous as used herein with reference to a nucleic acid (e.g., a gene) (or a protein) and a host refers to a nucleic acid (or protein) that does occur in (and can be obtained from) that particular host as it is found in nature.
  • a cell “endogenously expressing” a nucleic acid (or protein) expresses that nucleic acid (or protein) as does a host of the same particular type as it is found in nature.
  • a host “endogenously producing” or that "endogenously produces” a nucleic acid, protein, or other compound produces that nucleic acid, protein, or compound as does a host of the same particular type as it is found in nature.
  • one or more of the following polypeptides may be expressed in the host in addition to a polypeptide having fatty acid O-methyltransf erase activity or a polypeptide having alcohol O-acetyltransf erase activity: a monooxygenase, an esterase, a demethylase, a ⁇ - ketothiolase, an acetyl-CoA carboxylase, a ⁇ -ketoacyl-facpj synthase, a 3-hydroxyacyl- CoA dehydrogenase, a 3-oxoacyl-CoA reductase, an enoyl-CoA hydratase, a trans-2- enoyl-CoA reductase, a thioesterase, an aldehyde dehydrogenase, a butanal
  • dehydrogenase a monooxygenase in, for example, the CYP4F3B family, an alcohol dehydrogenase, a 7-oxoheptanoate dehydrogenase, a 6-oxohexanoate dehydrogenase, a 5-oxopentanoate dehydrogenase, a ⁇ -transaminase, a 6-hydroxyhexanoate
  • dehydrogenase a carboxylate reductase, a deacetylase, or m N-acetyl transferase.
  • a carboxylate reductase a phosphopantetheinyl transferase also can be expressed as it enhances activity of the carboxylate reductase.
  • an electron transfer chain protein such as an oxidoreductase and/or ferredoxin polypeptide also can be expressed.
  • a recombinant host can include at least one exogenous nucleic acid encoding a polypeptide having (i) fatty acid O-methyltransf erase activity or alcohol O-acetyltransf erase activity, (ii) monooxygenase activity, and (iii) esterase or demethylase activity.
  • a recombinant host can include at least one exogenous nucleic acid encoding a polypeptide having fatty acid O-methyltransf erase and a polypeptide having monooxygenase activity, wherein the host produces 5- hydro xypentanoate methyl ester.
  • a host further can include a polypeptide having demethylase or esterase activity and further produce 5-hydroxypentanoate.
  • the recombinant host also can include at least one exogenous nucleic acid encoding a polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl-facpj synthase activity, a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity or a polypeptide having 3-oxoacyl-CoA reductase activity, a polypeptide having enoyl-CoA hydratase activity, and a polypeptide having trans-2-enoyl-CoA reductase activity to produce C5 precursor molecules such as pentanoyl-CoA.
  • Such a host further can include one or more of (e.g., two or three of) an exogenous polypeptide having thioesterase activity, a polypeptide having aldehyde dehydrogenase activity or a polypeptide having butanal dehydrogenase activity, and produce pentanoate as a C5 precursor molecule.
  • an exogenous polypeptide having thioesterase activity e.g., two or three of
  • a polypeptide having aldehyde dehydrogenase activity or a polypeptide having butanal dehydrogenase activity e.g., pentanoate as a C5 precursor molecule.
  • a recombinant host can include at least one exogenous nucleic acid encoding a polypeptide having alcohol O-acetyltransf erase activity and a polypeptide having monooxygenase activity, wherein the host produces pentanoic acid pentyl ester.
  • a host further can include a polypeptide having esterase activity and further produce 5-hydroxypentanoate and/or 1,5-pentanediol.
  • the recombinant host also can include at least one exogenous nucleic acid encoding a polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl-facpj synthase activity, a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity or a polypeptide having 3-oxoacyl-CoA reductase activity, a polypeptide having enoyl-CoA hydratase activity, and a polypeptide having trans-2-enoyl-CoA reductase activity to produce C5 precursor molecules such as pentanoyl-CoA.
  • Such a host further can include one or more of (e.g., two or three of) an exogenous polypeptide having aldehyde dehydrogenase activity a polypeptide having alcohol dehydrogenase activity, a polypeptide having butanal dehydrogenase activity, a polypeptide having carboxylate reductase activity or a polypeptide having thioesterase activity and produce pentanol as a C5 precursor molecule.
  • a recombinant host producing 5-hydroxypentanoate further can include one or more polypeptides having an activity of a monooxygenase (e.g., in the CYP4F3B family) an alcohol dehydrogenase, an aldehyde dehydrogenase, a 6-hydroxyhexanoate dehydrogenase, a 7-oxoheptanoate dehydrogenase, a 6-oxohexanoate dehydrogenase, a 5-hydroxypentanoate dehydrogenase, a 4-hydroxybutyrate dehydrogenase or a 5- oxopentanoate dehydrogenase, and produce glutaric acid.
  • a monooxygenase e.g., in the CYP4F3B family
  • an alcohol dehydrogenase e.g., in the CYP4F3B family
  • an alcohol dehydrogenase e.g., in the
  • a recombinant host further can include a polypeptide having monooxygenase activity and produce glutaric acid.
  • a recombinant host further can include a polypeptide having the activity of (i) an alcohol dehydrogenase, a 6-hydroxyhexanoate dehydrogenase, a 5-hydroxypentanoate dehydrogenase, or a 4-hydroxybutyrate dehydrogenase or (ii) an aldehyde dehydrogenase, a 7-oxoheptanoate dehydrogenase, a 6-oxohexanoate dehydrogenase, or a 5-oxopentanoate dehydrogenase, and produce glutaric acid.
  • a recombinant host producing 5-hydroxypentanoate further can include one or more polypeptides having the activity of a transaminase, a 6-hydroxyhexanoate dehydrogenase, a 5-hydroxypentanoate dehydrogenase, a 4-hydroxybutyrate
  • a recombinant host producing 5-hydroxypentanoate further can include a polypeptide having ⁇ -transaminase activity and either a polypeptide having 6- hydroxyhexanoate dehydrogenase activity or having alcohol dehydrogenase activity.
  • a recombinant host producing 5-aminopentanoate, 5-hydroxypentanoate, glutarate semialdehyde or 1,5-pentanediol further can include one or more of a polypeptide having carboxylate reductase activity, a polypeptide having ⁇ -transaminase activity, a polypeptide having deacetylase activity a polypeptide having N-acetyl transferase activity, or a polypeptide having alcohol dehydrogenase activity, and produce cadaverine.
  • a recombinant host further can include each of a polypeptide having carboxylate reductase activity, a polypeptide having ⁇ -transaminase activity, a polypeptide having deacetylase activity and a polypeptide having N-acetyl transferase activity. In some embodiments, a recombinant host further can include a polypeptide having carboxylate reductase activity and a polypeptide having ⁇ - transaminase activity.
  • a recombinant host further can include a polypeptide having carboxylate reductase activity, a polypeptide having ⁇ -transaminase activity, and a polypeptide having alcohol dehydrogenase activity.
  • a polypeptide having carboxylate reductase activity a polypeptide having ⁇ -transaminase activity
  • a polypeptide having alcohol dehydrogenase activity a polypeptide having alcohol dehydrogenase activity.
  • an additional ⁇ - transaminase may not be necessary to produce cadaverine.
  • the host includes a second exogenous polypeptide having ⁇ -transaminase activity that differs from the first exogenous polypeptide having ⁇ -transaminase activity.
  • a recombinant host producing 5-hydroxypentanoic acid further can include one or more of a polypeptide having carboxylate reductase activity and a polypeptide having alcohol dehydrogenase activity, and produce 1,5-pentanediol.
  • the enzymes can be from a single source, i.e., from one species or genus, or can be from multiple sources, i.e., different species or genera.
  • Nucleic acids encoding the enzymes described herein have been identified from various organisms and are readily available in publicly available databases such as GenBank or EMBL.
  • the hosts contain an exogenous nucleic acid encoding the enzyme.
  • any of the enzymes described herein that can be used for production of one or more C5 building blocks can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%)) to the amino acid sequence of the corresponding wild-type enzyme.
  • sequence identity can be determined on the basis of the mature enzyme (e.g., with any signal sequence removed) or on the basis of the immature enzyme (e.g., with any signal sequence included).
  • the initial methionine residue may or may not be present on any of the enzyme sequences described herein.
  • a polypeptide having thioesterase activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of an Escherichia coli thioesterase encoded by tesB (see GenBank Accession No.
  • AAA24665.1 SEQ ID NO: 1
  • a Lactobacillus brevis thioesterase GenBank Accession No. ABJ63754.1 , SEQ ID NO:33
  • a Lactobacillus plantarum thioesterase GenBank Accession No. CCC58182.1, SEQ ID NO:34. See FIG. 10.
  • a polypeptide having carboxylate reductase activity described herein can have at least 70%> sequence identity (homology) (e.g., at least 75%, 80%>, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Mycobacterium marinum (see Genbank Accession No. ACC40567.1, SEQ ID NO: 2), a Mycobacterium smegmatis (see Genbank Accession No. ABK71854.1, SEQ ID NO: 3), a Segniliparus rugosus (see Genbank Accession No.
  • EFV11917.1, SEQ ID NO: 4 a Mycobacterium smegmatis (see Genbank Accession No. ABK75684.1, SEQ ID NO: 5), a Mycobacterium massiliense (see Genbank Accession No. EIV11143.1, SEQ ID NO: 6), or a Segniliparus rotundus (see Genbank Accession No. ADG98140.1, SEQ ID NO: 7) carboxylate reductase. See, FIG. 10.
  • a polypeptide having ⁇ -transaminase activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%>, 85%, 90%>, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Chromobacterium violaceum (see Genbank Accession No. AAQ59697.1, SEQ ID NO: 8), a Pseudomonas aeruginosa (see Genbank Accession No. AAG08191.1, SEQ ID NO: 9), a Pseudomonas syringae (see Genbank Accession No.
  • AAY39893.1, SEQ ID NO: 10 a Rhodobacter sphaeroides (see Genbank Accession No. ABA81135.1, SEQ ID NO: 11), an Escherichia coli (see Genbank Accession No. AAA57874.1 , SEQ ID NO: 12), or a Vibrio fluvialis (see Genbank Accession No. AEA39183.1, SEQ ID NO: 13) o> transaminase.
  • Some of these co-transaminases are diamine co-transaminases. See, FIG. 10.
  • a polypeptide having monooxygenase activity described herein can have at least 70%> sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Polaromonas sp. JS666 monooxygenase (see Genbank Accession No. ABE47160.1, SEQ ID NO: 14), a Mycobacterium sp. HXN-1500 monooxygenase (see Genbank
  • a polypeptide having oxidoreductase activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Polaromonas sp. JS666 oxidoreductase (see Genbank Accession No. ABE47159.1, SEQ ID NO: 17) or a Mycobacterium sp. HXN-1500 oxidoreductase (see Genbank Accession No. CAH04397.1 , SEQ ID NO: 18). See, FIG. 10.
  • sequence identity e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • a polypeptide having ferredoxin activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Polaromonas sp. JS666 ferredoxin (see Genbank Accession No. ABE47158.1, SEQ ID NO: 19) or a Mycobacterium sp. HXN-1500 ferredoxin (see Genbank Accession No. CAH04398.1, SEQ ID NO: 20). See, FIG. 10.
  • sequence identity e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • a polypeptide having phosphopantetheinyl transferase activity described herein can have at least 70%> sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Bacillus subtilis phosphopantetheinyl transferase (see Genbank Accession No. CAA44858.1, SEQ ID NO: 21) or a Nocardia sp. NRRL 5646
  • a polypeptide having fatty acid O-methyltransf erase activity described herein can have at least 70%> sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Mycobacterium marinum (see GenBank Accession No.
  • a polypeptide having alcohol O-acetyltransf erase activity described herein can have at least 70%> sequence identity (homology) (e.g., at least 75%, 80%>, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Saccharomyces cerevisiae (see GenBank Accession No. CAA85138.1, SEQ ID NO: 26) alcohol O-acetytransf erase. See FIG. 10.
  • sequence identity e.g., at least 75%, 80%>, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • a polypeptide having esterase activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Pseudomonas fluorescens (see GenBank Accession No. AAC60471.2, SEQ ID NO: 27) esterase. See FIG. 10.
  • sequence identity e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • a polypeptide having alkane 1-monooxygenase activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%>, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Pseudomonas putida alkane 1-monooxygenase (see Genbank Accession No. CAB51047.1, SEQ ID NO: 28).
  • sequence identity e.g., at least 75%, 80%>, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • a polypeptide having cytochrome P450 monooxygenase activity described herein can have at least 70%> sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Candida maltose cytochrome P450 (see Genbank Accession No: BAA00371.1, SEQ ID NOs: 29).
  • sequence identity e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • a polypeptide having butanal dehydrogenase activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Salmonella enterica subsp. enterica serovar Typhimurium butanal dehydrogenase (see GenBank Accession No. AAD39015, SEQ ID NO:30).
  • a polypeptide having syringate O-demethylase activity described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Sphingomonas paucimobilis demethylase (see, GenBank Accession No. BAD61059.1 and GenBank Accession No. BAC59257.1, SEQ ID NOs: 31 and 32, respectively).
  • sequence identity e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • the percent identity (homology) between two amino acid sequences can be determined as follows. First, the amino acid sequences are aligned using the BLAST 2 Sequences (B12seq) program from the stand-alone version of BLASTZ containing BLASTP version 2.0.14. This stand-alone version of BLASTZ can be obtained from Fish & Richardson's web site (e.g., www.fr.com/blast/) or the U.S. government's National Center for Biotechnology Information web site (www.ncbi.nlm.nih.gov). Instructions explaining how to use the B12seq program can be found in the readme file accompanying BLASTZ. B12seq performs a comparison between two amino acid sequences using the BLASTP algorithm.
  • B12seq performs a comparison between two amino acid sequences using the BLASTP algorithm.
  • B12seq are set as follows: -i is set to a file containing the first amino acid sequence to be compared (e.g., C: ⁇ seql .txt); -j is set to a file containing the second amino acid sequence to be compared (e.g., C: ⁇ seq2.txt); -p is set to blastp; -o is set to any desired file name (e.g., C: ⁇ output.txt); and all other options are left at their default setting.
  • -i is set to a file containing the first amino acid sequence to be compared (e.g., C: ⁇ seql .txt)
  • -j is set to a file containing the second amino acid sequence to be compared (e.g., C: ⁇ seq2.txt)
  • -p is set to blastp
  • -o is set to any desired file name (e.g., C: ⁇ output.txt); and all other options
  • the following command can be used to generate an output file containing a comparison between two amino acid sequences: C: ⁇ B12seq -i c: ⁇ seql .txt -j c: ⁇ seq2.txt -p blastp -o c: ⁇ output.txt. If the two compared sequences share homology (identity), then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology (identity), then the designated output file will not present aligned sequences. Similar procedures can be following for nucleic acid sequences except that blastn is used.
  • the number of matches is determined by counting the number of positions where an identical amino acid residue is presented in both sequences.
  • the percent identity (homology) is determined by dividing the number of matches by the length of the full-length polypeptide amino acid sequence followed by multiplying the resulting value by 100. It is noted that the percent identity (homology) value is rounded to the nearest tenth. For example, 78.11, 78.12, 78.13, and 78.14 is rounded down to 78.1, while 78.15, 78.16, 78.17, 78.18, and 78.19 is rounded up to 78.2. It also is noted that the length value will always be an integer.
  • nucleic acids can encode a polypeptide having a particular amino acid sequence.
  • the degeneracy of the genetic code is well known to the art; i.e., for many amino acids, there is more than one nucleotide triplet that serves as the codon for the amino acid.
  • codons in the coding sequence for a given enzyme can be modified such that optimal expression in a particular species (e.g., bacteria or fungus) is obtained, using appropriate codon bias tables for that species.
  • Functional fragments of any of the enzymes described herein can also be used in the methods of the document.
  • the term "functional fragment” as used herein refers to a peptide fragment of a protein that is shorter than the full-length immature protein protein and has at least 25% (e.g., at least: 30%; 40%; 50%; 60%; 70%; 75%; 80%; 85%; 90%; 91%; 92%; 93%; 94%; 95%; 96%; 97%; 98%; 99%; 100%; or even greater than 100%) of the activity of the corresponding mature, full-length, wild-type protein.
  • the functional fragment can generally, but not always, be comprised of a continuous region of the protein, wherein the region has functional activity.
  • This document also provides (i) functional variants of the enzymes used in the methods of the document and (ii) functional variants of the functional fragments described above.
  • Functional variants of the enzymes and functional fragments can contain additions, deletions, or substitutions relative to the corresponding wild-type sequences.
  • Enzymes with substitutions will generally have not more than 50 (e.g., not more than one, two, three, four, five, six, seven, eight, nine, ten, 12, 15, 20, 25, 30, 35, 40, or 50) amino acid substitutions (e.g., conservative substitutions). This applies to any of the enzymes described herein and functional fragments.
  • a conservative substitution is a substitution of one amino acid for another with similar characteristics.
  • Conservative substitutions include substitutions within the following groups: valine, alanine and glycine; leucine, valine, and isoleucine; aspartic acid and glutamic acid; asparagine and glutamine; serine, cysteine, and threonine; lysine and arginine; and phenylalanine and tyrosine.
  • the nonpolar hydrophobic amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Any substitution of one member of the above-mentioned polar, basic or acidic groups by another member of the same group can be deemed a conservative substitution. By contrast, a nonconservative substitution is a substitution of one amino acid for another with dissimilar characteristics.
  • Deletion variants can lack one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid segments (of two or more amino acids) or non-contiguous single amino acids.
  • Additions include fusion proteins containing: (a) any of the enzymes described herein or a fragment thereof; and (b) internal or terminal (C or N) irrelevant or heterologous amino acid sequences.
  • heterologous amino acid sequences refers to an amino acid sequence other than (a).
  • a heterologous sequence can be, for example a sequence used for purification of the recombinant protein (e.g., FLAG, polyhistidine (e.g., hexahistidine), hemagglutinin (HA), glutathione-S-transferase (GST), or maltosebinding protein (MBP)).
  • Heterologous sequences also can be proteins useful as detectable markers, for example, luciferase, green fluorescent protein (GFP), or chloramphenicol acetyl transferase (CAT).
  • the fusion protein contains a signal sequence from another protein.
  • the fusion protein can contain a carrier (e.g., KLH) useful, e.g., in eliciting an immune response for antibody generation) or ER or Golgi apparatus retention signals.
  • a carrier e.g., KLH
  • Heterologous sequences can be of varying length and in some cases can be a longer sequences than the full-length target proteins to which the heterologous sequences are attached.
  • Engineered hosts can naturally express none or some (e.g., one or more, two or more, three or more, four or more, five or more, or six or more) of the enzymes of the pathways described herein.
  • a pathway within an engineered host can include all exogenous enzymes, or can include both endogenous and exogenous enzymes.
  • Engineered hosts can be referred to as recombinant hosts or recombinant host cells.
  • recombinant hosts can include nucleic acids encoding one or more of a polypeptide having fatty acid O- methyltransf erase activity, a polypeptide having alcohol O-acetyltransferase activity, a polypeptide having dehydrogenase activity, a polypeptide having ⁇ -ketothiolase activity, a polypeptide having ⁇ -ketoacyl-facpj synthase activity, a polypeptide having carboxylase activity a polypeptide having reductase activity, a polypeptide having hydratase activity, a polypeptide having thioesterase activity, a polypeptide having monooxygenase activity, a polypeptide having demethylase activity, a polypeptide having esterase activity, or a polypeptide having transaminase activity as described herein.
  • the production of one or more C5 building blocks can be performed in vitro using the isolated enzymes described herein, using a lysate (e.g., a cell lysate) from a host microorganism as a source of the enzymes, or using a plurality of lysates from different host microorganisms as the source of the enzymes.
  • a lysate e.g., a cell lysate
  • C3-8 hydroxyalkyl refers to a saturated hydrocarbon group that may be straight-chain or branched, and is substituted by at least one hydro xyl (i.e., hydroxy or OH) group.
  • the C3-8 hydroxyalkyl refers to refers to a saturated hydrocarbon group that may be straight-chain or branched, and is substituted by at least one terminal hydro xyl (OH) group.
  • the alkyl group contains 4 to 8, 4 to 7, 4 to 6, 4 to 5, 5 to 8, 5 to 7, 5 to 6, 6 to 8, 6 to 7, or 7 to 8 carbon atoms.
  • the C3-8 hydroxyalkyl is a group of the following formula:
  • the method comprises:
  • the C4-9 carboxylic acid group contains 4 to 9, 4 to 8, 4 to 7, 4 to 6, 4 to 5, 5 to 9, 5 to 8, 5 to 7, 5 to 6, 6 to 9, 6 to 8, 6 to 7, 7 to 9, 7 to 8, or 8 to 9 carbon atoms.
  • Exemplary C4-9 carboxylic acids include butanoic acid (i.e., butanoate), pentanoic acid (i.e., pentanoate), hexanoic acid (i.e., hexanoate), heptanoic acid (i.e., heptanoate), octanoic acid (e.g., octanoate), nonanoic acid (i.e., nonanoate), 2- methylpentanoic acid (i.e., 2-methylpentanoate), 3-methylpentanoic acid (i.e., 3- methylpentanoate), and 4-methylpentanoic acid (i.e., 4-methylpentanoate).
  • the C4-9 carboxylic acid is pentanoic acid (i.e., pentanoate).
  • C3-8 alkyl refers to a saturated hydrocarbon group that may be straight- chain or branched, having 3 to 8 carbon atoms.
  • the alkyl group contains 4 to 8, 4 to 7, 4 to 6, 4 to 5, 5 to 8, 5 to 7, 5 to 6, 6 to 8, 6 to 7, or 7 to 8, carbon atoms.
  • Example alkyl moieties include n-butyl, isobutyl, sec-butyl, tert- butyl, n-pentyl, z ' so-pentyl, neo-pentyl, n-hexyl, n-heptyl, and n-octyl.
  • the C3-8 alkyl is a roup of the following formula:
  • the method comprises:
  • the C4-9 carboxylic acid is enzymatically converted to the (C3-8 ester using a polypeptide having fatty acid O-methyltransf erase activity.
  • the polypeptide having fatty acid O-methyltransf erase activity has at least 70% sequence identity to an amino acid sequence set forth in SEQ ID NO:23, SEQ ID NO:24, or SEQ ID NO:25.
  • the (C 3-8 ester is enzymatically converted to the (C 3-8 ester using a polypeptide having monooxygenase activity.
  • the monooxygenase is classified under EC 1.14.14.- or EC 1.14.15.-.
  • the monooxygenase has at least 70% sequence identity to an amino acid sequence set forth in SEQ ID NO:28 or SEQ ID NO:
  • the C4-9 carboxylic acid is enzymatically produced from C4-9 alkanoyl-CoA.
  • C4-9 alkanoyl-CoA refers to a compound having the following formula:
  • the C3-8 alkyl group is as defined herein.
  • the C3-8 alkyl is a group of the following formula:
  • a polypeptide having thioesterase activity enzymatically produces the C4-9 carboxylic acid from C4-9 alkanoyl-CoA.
  • the thioesterase has at least 70%> sequence identity to the amino acid sequence set forth in SEQ ID NO: l .
  • a polypeptide having butanal dehydrogenase activity and a polypeptide having aldehyde dehydrogenase activity enzymatically produces the C4-9 carboxylic acid from the C4-9 alkanoyl-CoA.
  • pentanoate is enzymatically converted to pentanoate methyl ester using a polypeptide having fatty acid O-methyltransf erase activity.
  • the polypeptide having fatty acid O-methyltransf erase activity has at least 70% sequence identity to an amino acid sequence set forth in SEQ ID NO:23, SEQ ID NO:24, or SEQ ID NO:25.
  • the polypeptide having fatty acid O- methyltransf erase activity is classified under EC 12.1.1.15.
  • pentanoate methyl ester is enzymatically converted to 5- hydroxypentanoate methyl ester using a polypeptide having monooxygenase activity.
  • the polypeptide having monooxygenase activity has at least 70%> sequence identity to an amino acid sequence set forth in SEQ ID NO:28 or SEQ ID NO:29.
  • the polypeptide having monooxygenase activity is classified under EC 1.14.14.- or EC 1.14.15.-.
  • pentanoate is enzymatically produced from pentanoyl- CoA.
  • a polypeptide having thioesterase activity enzymatically produces pentanoate from pentanoyl-CoA.
  • the polypeptide having thioesterase activity has at least 70%> sequence identity to the amino acid sequence set forth in SEQ ID NO: l .
  • C4-9 alkyl refers to a saturated hydrocarbon group that may be straight-chain or branched, having 4 to 9 carbon atoms.
  • the alkyl group contains 4 to 9, 4 to 8, 4 to 7, 4 to 6, 4 to 5, 5 to 9, 5 to 8, 5 to 7, 5 to 6, 6 to 9, 6 to 8, 6 to 7, 7 to 9, 7 to 8, or 8 to 9 carbon atoms.
  • Example alkyl moieties include n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, z ' so-pentyl, neo- pentyl, n-hexyl, n-heptyl, n-octyl, and n-nonyl.
  • one of the alkyl groups is substituted by at least one terminal hydroxy group.
  • each of the alkyl groups is substituted by at least one terminal hydroxy group.
  • one of the alkyl groups is substituted by one terminal hydroxy group.
  • each of the alkyl groups is substituted by one terminal hydroxy group.
  • the method includes:
  • the alcohol O-acetyltransf erase has at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: 26.
  • the polypeptide having monooxygenase activity is classified under EC 1.14.14.- or EC 1.14.15.-.
  • C4-9 hydroxyalkanoate refers to a compound having the following formula:
  • Example C4-9 hydroxyalkanoates include, but are not limited to, 5-hydroxypentanoate (i.e., 5-hydroxypentanoic acid), 4- hydroxypentanoate (i.e., 4-hydroxypentanoic acid), 3-hydroxypentanoate (i.e., 3- hydroxypentanoic acid), and the like. It is understood by those skilled in the art that the specific form will depend on pH (e.g., neutral or ionized forms, including any salt forms thereof).
  • the C3-8 hydroxyalkyl is a group having the following formula:
  • pentanoic acid pentyl ester b) enzymatically converting pentanoic acid pentyl ester to any of 5- hydroxypentanoic acid pentyl ester, 5-hydroxypentanoic acid 5-hydroxypentyl ester, or pentanoic acid 5-hydroxypentyl ester.
  • pentanoyl-CoA is enzymatically converted to pentanoic acid pentyl ester using a polypeptide having alcohol O-acetyltransf erase activity.
  • the polypeptide having alcohol O-acetyltransf erase activity has at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: 26.
  • pentanoic acid pentyl ester is enzymatically converted to any of 5-hydroxypentanoic acid pentyl ester, 5-hydroxypentanoic acid 5-hydroxypentyl ester and/or pentanoic acid 5-hydroxypentyl ester using a polypeptide having
  • the polypeptide having monooxygenase activity is classified under EC 1.14.14.- or EC 1.14.15.-.
  • the method further includes enzymatically converting 5- hydroxypentanoic acid 5-hydroxypentyl ester or 5-hydroxypentanoic acid pentyl ester to 5-hydroxypentanoate.
  • a polypeptide having esterase activity enzymatically converts 5-hydroxypentanoic acid 5-hydroxypentyl ester or 5- hydroxypentanoic acid pentyl ester to 5-hydroxypentanoate.
  • the method can include enzymatically converting 5- hydroxypentanoic acid 5-hydroxypentyl ester or pentanoic acid 5-hydroxypentyl ester to 1,5-pentanediol.
  • a polypeptide having esterase activity enzymatically converts 5-hydroxypentanoic acid 5-hydroxypentyl ester or pentanoic acid 5-hydroxypentyl ester to 1,5-pentanediol.
  • the method further includes enzymatically converting 5- hydroxypentanoic acid pentyl ester, 5-hydroxypentanoic acid 5-hydroxypentyl ester, or pentanoic acid 5-hydroxypentyl ester to 5-hydro xypentanoate and/or 1,5-pentanediol.
  • a polypeptide having esterase activity enzymatically converts 5- hydroxypentanoic acid pentyl ester, 5-hydroxypentanoic acid 5-hydroxypentyl ester, or pentanoic acid 5-hydroxypentyl ester to 5-hydro xypentanoate and/or 1,5-pentanediol.
  • the method further includes enzymatically converting 1,5- pentanediol to 5-hydroxypentanal.
  • a polypeptide having alcohol dehydrogenase activity enzymatically converts 1,5-pentanediol to 5-hydroxypentanal.
  • the method further includes enzymatically converting 5- hydroxypentanal to 5-hydro xypentanoate.
  • a polypeptide having aldehyde dehydrogenase activity enzymatically converts 5-hydroxypentanal to 5- hydro xypentanoate.
  • the method further includes enzymatically converting 5- hydroxypentanoate methyl ester to 5-hydro xypentanoate.
  • a polypeptide having demethylase or esterase activity enzymatically converts 5- hydro xypentanoate methyl ester to 5-hydro xypentanoate.
  • the method further includes enzymatically converting 5- hydroxypentanoate to a product selected from the group consisting of glutaric acid, glutarate semialdehyde, 5-aminopentanoate, cadaverine, and 1,5-pentanediol.
  • the method includes enzymatically converting 5- hydro xypentanoate to glutarate semialdehyde using a polypeptide having alcohol dehydrogenase activity, a polypeptide having 6-hydroxyhexanoate dehydrogenase activity, a polypeptide having 5-hydroxypentanoate dehydrogenase activity, a polypeptide having 4-hydroxybutyrate dehydrogenase activity, or a polypeptide having monooxygenase activity.
  • the method further includes enzymatically converting glutarate semialdehyde to glutaric acid using a polypeptide having 7-oxoheptanoate dehydrogenase activity, a polypeptide having 6-oxohexanoate dehydrogenase activity, a polypeptide having 5-oxopentanoate dehydrogenase activity, a polypeptide having aldehyde dehydrogenase activity, or a polypeptide having monooxygenase activity.
  • the method further includes enzymatically converting glutarate semialdehyde to 5-aminopentanoate.
  • a ⁇ -transaminase enzymatically converts glutarate semialdehyde to 5-aminopentanoate.
  • the method further includes enzymatically converting 5- aminopentanoate to cadaverine. In some embodiments, the method further includes enzymatically converting glutarate semialdehyde to cadaverine. In some embodiments, glutarate semialdehyde or 5-aminopentanoate is enzymatically converted to cadaverine using a polypeptide having carboxylate reductase activity and a polypeptide having ⁇ - transaminase activity and optionally one or more of a polypeptide having N-acetyl transferase activity, a polypeptide having acetylputrescine deacetylase activity, and a polypeptide having alcohol dehydrogenase activity.
  • 5-hydroxypentanoate is enzymatically converted to 1,5- pentanediol using a polypeptide having carboxylate reductase activity and a polypeptide having alcohol dehydrogenase activity.
  • said method further comprises enzymatically converting 1,5-pentanediol to cadaverine.
  • a polypeptide having alcohol dehydrogenase activity and a polypeptide having ⁇ -transaminase activity enzymatically converts 1,5-pentanediol cadaverine.
  • a polypeptide having carboxylate reductase activity, a polypeptide having ⁇ -transaminase activity, and a polypeptide having alcohol dehydrogenase activity enzymatically converts 5-hydroxypentanoate to cadaverine.
  • the ⁇ -transaminase has at least 70% sequence identity to any one of the amino acid sequences set forth in SEQ ID NO. 8 - 13.
  • pentanoyl-CoA is produced from acetyl-CoA and propanoyl-CoA via two cycles of CoA-dependent carbon chain elongation.
  • each of said two cycles of CoA-dependent carbon chain elongation comprises using a polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl-facpj synthase activity, a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity or a polypeptide having 3-oxoacyl-CoA reductase activity, a polypeptide having enoyl-CoA hydratase activity, and a polypeptide having trans-2-enoyl-CoA reductase activity to form pentanoyl-CoA from acetyl-Co A and propanoyl-CoA.
  • pentanoate methyl ester can be formed from pentanoate using a polypeptide having fatty acid O-methyltransf erase activity, such as the fatty acid O-methyltransf erase classified, for example, under EC 2.1.1.15.
  • a polypeptide having fatty acid O-methyltransf erase activity such as the fatty acid O-methyltransf erase classified, for example, under EC 2.1.1.15.
  • the polypeptide having fatty acid O-methyltransf erase activity can be obtained from
  • Mycobacterium marinum GenBank Accession No. ACC41782.1. SEQ ID NO:23
  • Mycobacterium smegmatis see GenBank Accession No. ABK73223.1 , SEQ ID NO: 24
  • ox Pseudomonas putida see GenBank Accession No. CAA39234.1, SEQ ID NO: 25.
  • Pentanoate methyl ester can be converted to 5-hydroxypentanoate methyl ester using a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC 1.14.15.- (e.g., EC 1.14.15.1 or EC 1.14.15.3)
  • a polypeptide having monooxygenase activity can be, for example, from the CYP153A family (SEQ ID NOs:14-16), the CYP52A3 family (See Genbank Accession No:
  • 5-hydroxypentanoate methyl ester can be converted to 5-hydroxypentanoate using a polypeptide having demethylase activity classified, for example, under EC 2.1.1.- such as the gene product of ligM (s ⁇ GenBank Accession No. BAD61059.1; SEQ ID NO:31) or desA (GenBank Accession No. BAC59257.1; SEQ ID NO:32) or using a polypeptide having esterase activity classified, for example under EC 3.1.1.- such as the gene product ofEstC (see GenBank Accession No. AAC60471.2, SEQ ID NO: 27).
  • a polypeptide having demethylase activity classified for example, under EC 2.1.1.- such as the gene product of ligM (s ⁇ GenBank Accession No. BAD61059.1; SEQ ID NO:31) or desA (GenBank Accession No. BAC59257.1; SEQ ID NO:32) or using a polypeptide having esterase activity classified, for example under EC 3.1.1.
  • pentanoyl-CoA can be converted to pentanoic acid pentyl ester using a polypeptide having alcohol O-acetyltransf erase activity classified, for example, under EC 2.3.1. -(e.g., EC 2.3.1.84) such as the gene product oiEhtl (Genbank Accession No: CAA85138.1, SEQ ID NO: 26).
  • Pentanoic acid pentyl ester can be converted to 5-hydroxypentanoic acid pentyl ester and/or 5-hydroxypentanoic acid 5-hydroxypentyl ester using a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC 1.14.15.- (e.g., EC 1.14.15.1 or EC 1.14.15.3)
  • a polypeptide having monooxygenase activity can be, for example, from the CYP153A family, the CYP52A3 family (Genbank Accession No: BAA00371.1, SEQ ID NO: 29) or the alkB family such as the gene product of alkBGT from Pseudomonas putida (Genbank Accession No. CAB51047.1, SEQ ID NO: 28). See, FIG. 7.
  • 5-hydroxypentanoic acid pentyl ester and 5-hydroxypentanoic acid 5- hydroxypentyl can be converted to 5-hydroxypentanoate using a polypeptide having esterase activity classified, for example, under EC 3.1.1.- (EC 3.1.1.1 or EC 3.1.1.6) such as the gene product of EstC (see GenBank Accession No. AAC60471.2, SEQ ID NO: 27).
  • the monooxygenase CYP153A family classified, for example, under
  • EC 1.14.15.- (e.g., EC 1.14.15.1 or EC 1.14.15.3) is soluble and has regio-specificity for terminal hydroxylation, accepting medium chain length substrates (see, e.g., Koch et ⁇ , Appl. Environ. Microbiol, 2009, 75(2), 337-344; Funhoff et al, 2006, J. Bacteriol, 188(44): 5220 - 5227; Van Beilen & Funhoff, Current Opinion in Biotechnology, 2005, 16, 308 - 314; Nieder and Shapiro, J. Bacteriol, 1975, 122(1), 93 - 98). Although nonterminal hydroxylation is observed in vitro for CYP153A, in vivo only 1 -hydroxylation occurs (see, Funhoff et al, 2006, supra).
  • the substrate specificity and activity of terminal monooxygenases has been broadened via successfully, reducing the chain length specificity of CYP153A to below C8 (Koch et al , 2009, supra).
  • pentanoate can be enzymatically formed from pentanoyl- CoA using a polypeptide having thioesterase activity classified under EC 3.1.2.-, such as the gene product of YciA, tesB (GenBank Accession No. AAA24665.1, SEQ ID NO: 1) or Acotl3 (Cantu et al, Protein Science, 2010, 19, 1281 - 1295; Zhuang et al,
  • acyl-[acp] thioesterases have C6 - C8 chain length specificity (see, for example, Jing et ah, 2011, BMC
  • pentanoate can be enzymatically formed from pentanoyl- CoA using a polypeptide having butanal dehydrogenase activity classified, for example, under EC 1.2.1.- such as EC 1.2.1.10 or EC 1.2.1.57 (see, e.g., GenBank Accession No. AAD39015, SEQ ID NO:30) (e.g., the gene product ofPduB or PduD) or an aldehyde dehydrogenase classified, for example, under EC 1.2.1.- such as EC 1.2.1.3 or EC 1.2.1.4 (see, Ho & Weiner, J. Bacteriol., 2005, 187(3): 1067 - 1073). See, FIG. 3.
  • pentanoyl-CoA can be formed from acetyl-CoA or propanoyl-CoA via two cycles of CoA-dependent carbon chain elongation using either NADH or NADPH dependent enzymes.
  • a CoA-dependent carbon chain elongation cycle comprises using a polypeptide having ⁇ -ketothiolase activity or a polypeptide having acetyl-CoA carboxylase activity and a polypeptide having ⁇ -ketoacyl-facpj synthase activity, a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity or a polypeptide having
  • 3-oxoacyl-CoA reductase activity a polypeptide having enoyl-CoA hydratase activity and a polypeptide having trans-2-enoyl-CoA reductase activity.
  • a polypeptide having ⁇ - ketothiolase activity can convert propanoyl-CoA to 3-oxopentanoyl-CoA and can convert pentanoyl-CoA to 3-oxopentanoyl-CoA.
  • a polypeptide having acetyl-CoA carboxylase activity can convert acetyl-CoA to malonyl-CoA.
  • a polypeptide having acetoacetyl-CoA synthase activity can convert malonyl-CoA to acetoacetyl-CoA.
  • a polypeptide having 3- hydroxybutyryl-CoA dehydrogenase activity can convert 3-oxopentanoyl-CoA to 3- hydroxypentanoyl CoA.
  • a polypeptide having 3-oxoacyl-CoA reductase/3 -hydroxyacyl- CoA dehydrogenase activity can convert 3-oxopentanoyl-CoA to 3-hydroxypentanoyl- CoA.
  • a polypeptide having enoyl-CoA hydratase activity can convert 3- hydroxypentanoyl-CoA to pent-2-enoyl-CoA and can convert 3-hydroxypentanoyl-CoA to pent-2-enoyl-CoA.
  • a polypeptide having trans-2-enoyl-CoA reductase activity can convert pent-2-enoyl-CoA to pentanoyl-CoA and can convert pent-2-enoyl-CoA to pentanoyl-CoA. See FIGs. 1 and 2.
  • a polypeptide having ⁇ -ketothiolase activity can be classified under EC 2.3.1.16, such as the gene product of bktB (See, e.g., Genbank Accession AAC38322.1).
  • the polypeptide having ⁇ -ketothiolase activity encoded by bktB from Cupriavidus necator accepts propanoyl-CoA and pentanoyl-CoA as substrates.
  • the CoA-activated C5 aliphatic backbone (3- oxopentanoyl-CoA) is produced (see, e.g., Haywood et ⁇ , FEMS Microbiology Letters, 1988, 52:91-96; Slater et al, J. Bacteriol, 1998, 180(8): 1979 - 1987).
  • the polypeptide having ⁇ -ketothiolase activity encoded by paaJ See, e.g., Genbank Accession No.
  • catF and pcaF can be classified under, for example, EC 2.3.1.174.
  • the polypeptide having ⁇ -ketothiolase activity encoded by paaJ condenses acetyl-CoA and succinyl-CoA to 3-oxoadipyl-CoA (see, for example, Fuchs et al, 2011, Nature Reviews Microbiology, 9, 803 - 816; Gobel et al, 2002, J. Bacteriol., 184(1), 216 - 223) See FIGs. 1 and 2.
  • a polypeptide having acetyl-CoA carboxylase activity can be classified, for example, under EC 6.4.1.2.
  • a polypeptide having ⁇ -ketoacyl- [acp] synthase activity can be classified, for example, under 2.3.1.180 such as the gene product of FabH from Staphylococcus aereus (Qiu et al. , 2005, Protein Science, 14: 2087 - 2094). See FIGs. 1 and 2.
  • a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity or a polypeptide having 3-oxoacyl-CoA dehydrogenase activity can be classified under EC 1.1.1.-.
  • dehydrogenase activity can be classified under EC 1.1.1.35, such as the gene product of fadB (FIG. 1); classified under EC 1.1.1.157, such as the gene product of hbd (can be referred to as a 3-hydroxybutyryl-CoA dehydrogenase) (FIG. 1); or classified under EC 1.1.1.36, such as the acetoacetyl-CoA reductase gene product of phaB (Liu & Chen, Appl. Microbiol. Biotechnol, 2007, 76(5): 1153 - 1159; Shen et ⁇ ., ⁇ . Environ. Microbiol, 2011, 77(9):2905 - 2915; Budde et al, J. Bacteriol, 2010, 192(20):5319 - 5328) (FIG. 2).
  • a polypeptide having 3-oxoacyl-CoA reductase activity can be classified under EC 1.1.1.100, such as the gene product of fabG (Budde et al , J. Bacteriol, 2010, 192(20):5319 - 5328; Nomura et ⁇ , ⁇ Environ. Microbiol, 2005, 71(8):4297 - 4306).
  • a polypeptide having enoyl-CoA hydratase activity can be classified under EC 4.2.1.17, such as the gene product of crt (Genbank Accession No. AAA95967.1) (FIG. 1), or classified under EC 4.2.1.119, such as the gene product of phaJ (Genbank Accession No.BAA21816.1) (FIG. 2) (Shen et al, 2011, supra; Fukui et al, J. Bacteriol, 1998, 180(3):667 - 673).
  • a polypeptide having trans-2-enoyl-CoA reductase activity can be classified under EC 1.3.1.38 (FIG. 2), EC 1.3.1.8 (FIG. 2), or EC 1.3.1.44 (FIG. 1), such as the gene product of ter (Genbank Accession No. AAW66853.1) (Nishimaki et al , J. Biochem. , 1984, 95: 1315 - 1321; Shen et al , 2011 , supra) or tdter (Genbank Accession No. AAS11092.1) (Bond- Watts et al, Biochemistry, 2012, 51 :6827 - 6837).
  • a terminal carboxyl group can be enzymatically formed using a polypeptide having thioesterase activity, a polypeptide having aldehyde dehydrogenase activity, a polypeptide having 7-oxoheptanoate dehydrogenase activity, a polypeptide having 6-oxohexanoate dehydrogenase activity, a polypeptide having 5- oxopentanoate dehydrogenase activity a polypeptide having monooxygenase activity, a polypeptide having esterase activity, or a polypeptide having demethylase activity.
  • the first terminal carboxyl group is enzymatically formed by a polypeptide having syringate O-demethylase activity classified under EC 2.1.1.- such as the gene products of ligM (see GenBank Accession No. BAD61059.1; SEQ ID NO:31) or desA (GenBank Accession No. BAC59257.1; SEQ ID NO:32) or an esterase classified under EC 3.1.1.- such as the gene product of EstC (see, e.g., GenBank
  • the first terminal carboxyl group is enzymatically formed by a polypeptide having aldehyde dehydrogenase activity classified, for example, under EC 1.2.1.3 or EC 1.2.1.4.
  • the second terminal carboxyl group leading to the synthesis of glutaric acid is enzymatically formed by a polypeptide having aldehyde dehydrogenase activity classified, for example, under EC 1.2.1.3 (see, Guerrillot & Vandecasteele, Eur. J. Biochem., 1977, 81, 185 - 192). See FIG. 4.
  • the second terminal carboxyl group leading to the synthesis of glutaric acid is enzymatically formed by a polypeptide having
  • dehydrogenase activity classified under EC 1.2.1.- such as a 5-oxopentanoate
  • dehydrogenase e.g., the gene product of CpnE
  • a 6-oxohexanoate dehydrogenase e.g., the gene product of ChnE from Acinetobacter sp.
  • a 7-oxoheptanoate dehydrogenase e.g., the gene product of ThnG from Sphingomonas macrogolitabida
  • a polypeptide having 5-oxopentanoate dehydrogenase activity can be classified under EC 1.2.1.20.
  • a polypeptide having 6-oxohexanoate dehydrogenase activity can be classified under EC 1.2.1.63.
  • a polypeptide having 7-oxoheptanoate dehydrogenase activity can be classified under EC 1.2.1.-. See, FIG. 4.
  • the second terminal carboxyl group leading to the synthesis of glutaric acid is enzymatically formed by a polypeptide having
  • cytochrome P450 family such as CYP4F3B
  • CYP4F3B see, e.g., Sanders et al., J. Lipid Research, 2005, 46(5): 1001-1008; Sanders et al., The FASEB Journal, 2008, 22(6):2064 - 2071). See, FIG. 4.
  • terminal amine groups can be enzymatically formed using a polypeptide having ⁇ -transaminase activity or a polypeptide having deacetylase activity.
  • the first terminal amine group leading to the synthesis of 5-aminopentanoic acid, 5-aminopentanal, or 5-aminopentanol is enzymatically formed by a ⁇ -transaminase classified, for example, under EC 2.6.1.- such as EC 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48, or EC 2.6.1.82 such as that obtained from
  • Chromobacterium violaceum (Genbank Accession No. AAQ59697.1, SEQ ID NO: 8), Pseudomonas aeruginosa (Genbank Accession No. AAG08191.1, SEQ ID NO: 9), Pseudomonas syringae (Genbank Accession No. AAY39893.1, SEQ ID NO: 10), Rhodobacter sphaeroides (Genbank Accession No. ABA81135.1, SEQ ID NO: 11), Vibrio fluvialis (Genbank Accession No. AAA57874.1, SEQ ID NO: 13), Streptomyces griseus, or Clostridium viride.
  • polypeptide having ⁇ -transaminase activity that can be used in the methods and hosts described herein is from Escherichia coli (Genbank Accession No. AAA57874.1, SEQ ID NO: 12).
  • Some of the polypeptides having ⁇ -transaminases activity classified, for example, under EC 2.6.1.29 or EC 2.6.1.82 are polypeptides having diamine ⁇ -transaminases activity (e.g., SEQ ID NO: 12).
  • Chromobacterium violaceum (Genbank Accession No. AAQ59697.1, SEQ ID NO: 8) has demonstrated analogous activity accepting 6-aminohexanoic acid as amino donor, thus forming the first terminal amine group in adipate semialdehyde (Kaulmann et al., Enzyme and Microbial Technology, 2007, 41, 628 - 637).
  • the reversible polypeptide having 4-aminobutyrate: 2-oxoglutarate transaminase activity from Streptomyces griseus has demonstrated analogous activity for the conversion of 6-aminohexanoate to adipate semialdehyde (Yonaha et al., Eur. J.
  • the second terminal amine group leading to the synthesis of cadaverine is enzymatically formed by a polypeptide having diamine transaminase activity.
  • the second terminal amino group can be enzymatically formed by a polypeptide having diamine transaminase activity classified, for example, under EC 2.6.1.-, e.g., EC 2.6.1.29 or classified, for example, under EC 2.6.1.82, such as the gene product of YgjG from E. coli (Genbank Accession No. AAA57874.1, SEQ ID NO: 12). See, FIG. 6.
  • the gene product of ygjG accepts a broad range of diamine carbon chain length substrates, such as putrescine, cadaverine and spermidine (Samsonova et al. , BMC Microbiology, 2003, 3:2).
  • the polypeptide having diamine transaminase activity from E.coli strain B has demonstrated activity for 1,7 diaminopentane (Kim, The Journal of Chemistry, 1964, 239(3), 783 - 786).
  • the second terminal amine group leading to the synthesis of cadaverine is enzymatically formed by a polypeptide having deacetylase activity classified, for example, under EC 3.5.1.62 such as a polypeptide having acetylputrescine deacetylase activity.
  • the polypeptide having acetylputrescine deacetylase activity from Micrococcus luteus K-1 1 accepts a broad range of carbon chain length substrates, such as acetylputrescine, acetylcadaverine and N 8 _acetylspermidine (see, for example, Suzuki et al, 1986, BBA - General Subjects, 882(1):140 - 142).
  • a terminal hydroxyl group can be enzymatically forming using a polypeptide having alcohol dehydrogenase activity.
  • the second terminal hydroxyl group leading to the synthesis of 1,7 pentanediol is enzymatically formed by a polypeptide having alcohol dehydrogenase activity classified under EC 1.1.1.- (e.g., EC 1.1.1.1, 1.1.1.2, 1.1.1.21, or 1.1.1.184).
  • a first terminal hydro xyl group can be enzymatically formed with a polypeptide having monoxygenase activity as discussed above with respect to the formation of 5- hydroxypentanoate methyl ester in FIG. 7.
  • pentanoyl-CoA can be converted to pentanoic acid pentyl ester using a polypeptide having alcohol O-acetyltransf erase activity classified, for example, under EC 2.3.1. -(84) such as the gene product of£7zti(Genbank Accession No: CAA85138.1, SEQ ID NO: 26).
  • Pentanoic acid pentyl ester can be converted to 5-hydroxypentanoic acid 5- hydroxypentyl ester using a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC 1.14.15.- (EC 1.14.15.1 or EC 1.14.15.3).
  • Pentanoic acid pentyl ester can be converted to pentanoic acid 5-hydroxypentyl ester using a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC 1.14.15.- (1,3).
  • a polypeptide having monooxygenase activity can be, for example, from the CYP153A family, the CYP52A3 family or the alkB family such as the gene product of alkBGT from Pseudomonas putida. See, FIG. 7.
  • Pentanoic acid 5-hydroxypentyl ester and 5-hydroxypentanoic acid 5- hydroxypentyl can be converted to 1,5-pentanediol using a polypeptide having esterase activity classified, for example, under EC 3.1.1.- (e.g., EC 3.1.1.1 or EC 3.1.1.6) such as the gene product of EstC (see GenBank Accession No. AAC60471.2, SEQ ID NO: 27).
  • EC 3.1.1.- e.g., EC 3.1.1.1 or EC 3.1.1.6
  • EstC see GenBank Accession No. AAC60471.2, SEQ ID NO: 27.
  • propanoyl-Coenzyme A is a precursor leading to one or more central precursors in the synthesis of one or more C5 building blocks (see, e.g., FIG. 9).
  • propanoyl-CoA is synthesized from the central metabolite succinyl-CoA by conversion of succinyl-CoA to (2R)-methylmalonyl-CoA by a polypeptide having methylmalonyl-CoA mutase activity classified, for example, under EC 5.4.99.2; followed by conversion to (2S)-methylmalonyl-CoA by a polypeptide having methylmalonyl-CoA epimerase activity classified, for example, under EC 5.1.99.1 ;
  • propanoyl-CoA is synthesized from the central metabolite, L-threonine, by conversion of L-threonine to 2-oxobutyrate by a polypeptide having threonine ammonia lyase activity classified, for example, under EC 4.3.1.19; followed by conversion to propanoyl-CoA by a polypeptide having 2-ketobutyrate formate-lyase activity classified, for example, under EC 2.3.1.- such as the gene product of tdcE (Tseng et ah, Microbial Cell Factories, 2010, 9:96). See, e.g., FIG. 9.
  • propanoyl-CoA is synthesized from 1,2-propanediol by conversion to propanal by a polypeptide having propanediol dehydratase activity classified, for example, under EC 4.2.1.28; followed by conversion to propanoyl-CoA by a polypeptide having CoA-dependent propionaldehyde dehydrogenase activity such as the gene product of pduP (Luo et al, Bioresource Technology, 2012, 103: 1- 6). See, e.g., FIG. 9.
  • propanoyl-CoA is synthesized from the carbon source, levulinic acid, by conversion of levulinic acid to levulinyl-CoA by a polypeptide having acyl-CoA synthetase or ligase activity classified, for example, under EC 6.2.1.-; followed by conversion to propanoyl-CoA by a transferase classified, for example, under EC 2.3.1.- (Jaremko and Yu, J. Biotechnol., 2011, 155:293 - 298). See, e.g., FIG. 9.
  • propanoyl-CoA is synthesized from the central metabolite, pyruvate, by conversion of pyruvate to L-lactate by a polypeptide having L-lactate dehydrogenase activity classified, for example, under EC 1.1.1.27; followed by conversion to lactoyl-CoA by a polypeptide having proprionate Co A-transf erase activity classified, for example, under EC 2.8.3.1; followed by conversion to propenoyl-CoA by a polypeptide having lactoyl-CoA dehydratase activity classified, for example, under EC 4.2.1.54; followed by conversion to propanoyl-CoA by a polypeptide having butyryl-CoA dehydrogenase activity classified, for example, under EC 1.3.8.1 or a polypeptide having medium-chain acyl-CoA dehydrogenase activity classified, for example, under EC 1.3.8.7. See, e.g., FIG. 9.
  • propanoyl-CoA is synthesized from the central metabolite, malonyl-CoA, by conversion of malonyl-CoA to malonate semialdehyde by a
  • pentanoyl-CoA is synthesized from propanoyl-CoA by conversion of propanoyl-CoA to 3-oxopentanoyl-CoA by a polypeptide having ⁇ - ketothiolase activity classified, for example, under EC 2.3.1.16, such as the gene product of bktB (Genbank Accession No. AAC38322.1) or classified, for example, under EC 2.3.1.174 such as the gene product of paaJ (Genbank Accession No.
  • AAA95967.1 followed by conversion of pent-2-enoyl- CoA to pentanoyl-CoA by a polypeptide having trans-2-enoyl-CoA reductase activity classified, for example, under EC 1.3.1.44 such as the gene product of ter (Genbank Accession No. AAW66853.1) or tdter (Genbank Accession No. AASl 1092.1); followed by conversion of pentanoyl-CoA to 3-oxo-pentanoyl-CoA by a polypeptide having ⁇ - ketothiolase activity classified, for example, under EC 2.3.1.16 such as the gene product of bktB (Genbank Accession No.
  • AAC38322.1 or classified, for example, under EC 2.3.1.174 such as the gene product of paaJ (Genbank Accession No. AAC54479.1); followed by conversion of 3-oxo-pentanoyl-CoA to (S) 3-hydroxypentanoyl-CoA by a polypeptide having 3-hydroxyacyl-CoA dehydrogenase activity classified, for example, under EC 1.1.1.35 such as the gene product of fadB or by a polypeptide having 3- hydroxyacyl-CoA dehydrogenase activity classified, for example, under EC 1.1.1.157 such as the gene product of hbd; followed by conversion of (S) 3-hydroxypentanoyl-CoA to pent-2-enoyl-CoA by a polypeptide having enoyl-CoA hydratase activity classified, for example, under EC 4.2.1.17 such as the gene product of crt (Genbank Accession No.
  • pentanoyl-CoA is synthesized from the central metabolite, propanoyl-CoA, by conversion of propanoyl-CoA to 3-oxopentanoyl-CoA by a polypeptide having ⁇ -ketothiolase activity classified, for example, under EC 2.3.1.16, such as the gene product of bktB; followed by conversion of 3-oxopentanoyl-CoA to (R) 3-hydroxypentanoyl-CoA by a polypeptide having 3-oxoacyl-CoA reductase activity classified, for example, under EC 1.1.1.100, such as the gene product of fadG or by a polypeptide having acetoacetyl-CoA reductase activity classified, for example, under EC 1.1.1.36 such as the gene product of phaB; followed by conversion of (R) 3- hydroxypentanoyl-CoA to pent-2-enoyl-CoA
  • dehydrogenase activity classified, for example, under EC 1.3.1.8; followed by conversion of pentanoyl-CoA to 3-oxo-pentanoyl-CoA by a polypeptide having ⁇ -ketothiolase activity classified, for example, under EC 2.3.1.16 such as the gene product of bktB (Genbank Accession No. AAC38322.1) or classified, for example, under EC 2.3.1.174 such as the gene product of paaJ (Genbank Accession No.
  • 3-oxopentanoyl-CoA can be synthesized from acetyl-CoA.
  • a polypeptide having acetyl-CoA carboxylase activity classified, for example, under EC 6.4.1.2 can be used to convert acetyl-CoA to malonyl-CoA, which can be converted to 3- oxopentanoyl-CoA using a polypeptide having ⁇ -ketoacyl-facpj synthase activity classified, for example, under EC 2.3.1.- such as EC 2.3.1.41, EC 2.3.1.179 or EC 2.3.1.180 such as the gene product of fabH. See, FIG. 1 and FIG. 2.
  • pentanoate is synthesized from pentanoyl-CoA by conversion of pentanoyl-CoA to pentanoate by a polypeptide having thioesterase activity classified, for example, under EC 3.1.2.- such as the gene product of YciA, tesB, Acotl3, a Lactobacillus brevis acyl-[acp] thioesterase (GenBank Accession No. ABJ63754.1, SEQ ID NO:33) or a Lactobacillus plantarum acyl-[acp] thioesterase (GenBank Accession No. ABJ63754.1, SEQ ID NO:33) or a Lactobacillus plantarum acyl-[acp] thioesterase (GenBank Accession No. ABJ63754.1, SEQ ID NO:33) or a Lactobacillus plantarum acyl-[acp] thioesterase (GenBank Accession No. ABJ
  • pentanoyl-CoA is converted to pentanal by a polypeptide having butanal dehydrogenase activity classified, for example, under EC 1.2.1.- such as EC 1.2.1.10 or EC 1.2.1.57 (see, e.g, GenBank Accession No. AAD39015, SEQ ID NO:30); followed by conversion of pentanal to pentanoate by a polypeptide having aldehyde dehydrogenase activity classified, for example, under EC 1.2.1.4 or EC 1.2.1.3. See FIG. 3.
  • pentanoate is synthesized from pentanoyl-CoA by conversion of pentanoyl-CoA to pentanoate by a polypeptide having thioesterase activity classified, for example, under EC 3.1.2.- such as the gene product of YciA, tesB or Acotl3, a Lactobacillus brevis acyl-[acp] thioesterase (GenBank Accession No.
  • CAA90836.1 or YqhD (from E. coli, GenBank Accession No. AAA69178.1) (see, e.g., Liu et al, Microbiology, 2009, 155, 2078 - 2085; Larroy et al, 2002, Biochem J, 361(Pt 1), 163 - 172; or Jarboe, 2011, Appl. Microbiol. Biotechnol., 89(2), 249 - 257) or the protein having GenBank Accession No. CAA81612.1 (from Geobacillus stearothermophilus). See, FIG. 3.
  • pentanoyl-CoA is converted to pentanal by a polypeptide having butanal dehydrogenase activity classified, for example, under EC 1.2.1.57 (see, e.g., GenBank Accession No. BAD61059.1, SEQ ID NO:31); followed by conversion of pentanal to pentanol by a polypeptide having alcohol dehydrogenase activity classified, for example, under EC 1.1.1.- such as EC 1.1.1.1, EC 1.1.1.2, EC 1.1.1.21, or EC
  • 5-hydroxypentanoate is synthesized from the central precursor, pentanoate, by conversion of pentanoate to pentanoate methyl ester using a polypeptide having fatty acid O-methyltransf erase activity classified, for example, under EC 2.1.1.15 (e.g., the fatty acid O-methyltransf erase from Mycobacterium marinum
  • GenBank Accession No. ACC41782.1. SEQ ID NO:23 Mycobacterium smegmatis (see GenBank Accession No. ABK73223.1 , SEQ ID NO: 24), or Pseudomonas putida (see GenBank Accession No.
  • CAA39234.1 SEQ ID NO: 25
  • a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC 1.14.15.- e.g., EC 1.14.15.1 or EC 1.14.15.3
  • EC 1.14.14.- e.g., EC 1.14.15.-
  • EC 1.14.15.1 or EC 1.14.15.3 a monooxygenase in the CYP153A, a CYP52A3 family, or alkB family
  • conversion to 5-hydroxypentanoate using a polypeptide having syringate O-demethylase activity classified under EC 2.1.1.- such as the gene products of HgM (see GenBank Accession No.
  • BAD61059.1; SEQ ID NO:31) or desA GeneBank Accession No. BAC59257.1 ; SEQ ID NO:32
  • a polypeptide having esterase activity classified under EC 3.1.1. such as the gene product of EstC (see GenBank Accession No. AAC60471.2, SEQ ID NO: 27) (Kim et al, 1994, Biosci. Biotech.
  • pentanoate can be enzymatically converted to 5- hydro xypentanoate by a polypeptide having monooxygenase activity (classified, for example, under EC 1.14.14.- or EC 1.14.15.- such as a monooxygenase in the CYP153A, the CYP52A3 family, and/or the gene product of alkB family.
  • a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC 1.14.15.- such as a monooxygenase in the CYP153A, the CYP52A3 family, and/or the gene product of alkB family.
  • pentanoyl-CoA can be converted to pentanoic acid pentyl ester using a polypeptide having alcohol O-acetyltransf erase activity classified, for example, under EC 2.3.1. -(84) such as the gene product oiEhtl (Genbank Accession No: CAA85138.1, SEQ ID NO: 25); followed by conversion to 5-hydroxypentanoic acid pentyl ester and/or 5-hydroxypentanoic acid 5-hydroxypentyl ester using a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC
  • a polypeptide having monooxygenase activity can be, for example, from the CYP153A family, the CYP52A3 family (Genbank Accession No: BAA00371.1, SEQ ID NO: 29) or the alkB family such as the gene product ofalkBGT from Pseudomonas putida (Genbank Accession No.
  • Glutarate semialdehyde can be synthesized by enzymatically converting 5- hydroxypentanoate to glutarate semialdehyde using a polypeptide having alcohol dehydrogenase activity classified, for example, under EC 1.1.1.- such as the gene product of YMR318C (classified, for example, under EC 1.1.1.2, see Genbank Accession No. CAA90836.1) (Larroy et al, 2002, Biochem J, 361(Pt 1), 163 - 172), cpnD (Iwaki et al, 2002, Appl Environ. Microbiol, 68(11):5671 - 5684) or gabD (Lutke-Eversloh &
  • the polypeptide having alcohol dehydrogenase activity encoded by YMR318C has broad substrate specificity, including the oxidation of C5 alcohols.
  • Glutarate semialdehyde can be enzymatically converted to glutaric acid using a polypeptide having aldehyde dehydrogenase activity classified, for example, under EC 1.2.1.- (3,16,20,63,79) such as a polypeptide having 7-oxoheptanoate dehydrogenase activity (e.g., the gene product of ThnG), a polypeptide having 6-oxohexanoate dehydrogenase activity (e.g., the gene product of ChnE), or a polypeptide having aldehyde dehydrogenase activity classified under EC 1.2.1.3. See FIG. 4.
  • a polypeptide having aldehyde dehydrogenase activity classified, for example, under EC 1.2.1.- (3,16,20,63,79) such as a polypeptide having 7-oxoheptanoate dehydrogenase activity (e.g., the gene product of ThnG), a poly
  • 5-aminopentanoate is synthesized from 5- hydroxypentanoate by conversion of 5-hydroxypentanoate to glutarate semialdehyde using a polypeptide having alcohol dehydrogenase activity classified, for example, under EC 1.1.1.- such as the gene product of YMR318C (classified, for example, under EC 1.1.1.2, see Genbank Accession No. CAA90836.1) (Larroy et al, 2002, Biochem J, 361(Pt 1), 163 - 172), cpnD (Iwaki et al, 2002, Appl. Environ.
  • a polypeptide having alcohol dehydrogenase activity classified, for example, under EC 1.1.1.- such as the gene product of YMR318C (classified, for example, under EC 1.1.1.2, see Genbank Accession No. CAA90836.1) (Larroy et al, 2002, Biochem J, 361(Pt 1), 163 -
  • cadaverine is synthesized from the central precursor 5- aminopentanoate by conversion of 5-aminopentanoate to 5-aminopentanal by a polypeptide having carboxylate reductase activity classified, for example, under EC 1.2.99.6 such as the gene product of car in combination with a phosphopantetheine transferase enhancer (e.g., encoded by a sfp gene from Bacillus subtilis or npt gene from Nocardia) or the gene products of GriC and GriD from Streptomyces griseus; followed by conversion of 5-aminopentanal to cadaverine by a polypeptide having co-trans aminase activity classified, for example, under EC 2.6.1.- such as 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29,
  • the polypeptide having carboxylate reductase activity encoded by the gene product of car and enhancer npt or sfp has broad substrate specificity, including terminal difunctional C4 and C5 carboxylic acids (Venkitasubramanian et al. , Enzyme and Microbial Technology, 2008, 42, 130 - 137).
  • cadaverine is synthesized from the central precursor 5- hydroxypentanoate (which can be produced as described in FIG. 7), by conversion of 5- hydroxypentanoate to 5-hydroxypentanal by a polypeptide having carboxylate reductase activity classified, for example, under EC 1.2.99.6 such as from a Mycobacterium marinum (see Genbank Accession No. ACC40567.1 , SEQ ID NO: 2), a Mycobacterium smegmatis (see Genbank Accession No. ABK71854.1, SEQ ID NO: 3), a Segniliparus rugosus (see Genbank Accession No.
  • EFV11917.1 SEQ ID NO: 4
  • a Mycobacterium massiliense see Genbank Accession No. EIV11143.1, SEQ ID NO: 6
  • a Segniliparus rotundus see Genbank Accession No. ADG98140.1, SEQ ID NO: 7
  • a phosphopantetheine transferase enhancer e.g., encoded by a sfp (Genbank Accession No. CAA44858.1, SEQ ID NO:21) gene from Bacillus subtilis or npt
  • CAA81612.1 followed by conversion to cadaverine classified, for example, under EC 2.6.1.- such as 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48, or EC 2.6.1.82 such as from a Chromobacterium violaceum (see Genbank Accession No.
  • cadaverine is synthesized from the central precursor 5- aminopentanoate by conversion of 5-aminopentanoate to N5-acetyl-5-aminopentanoate by a polypeptide having N-acetyltransf erase activity such as a polypeptide having lysine N-acetyltransj ' erase activity classified, for example, under EC 2.3.1.32; followed by conversion to N5-acetyl-5-aminopentanal by a polypeptide having carboxylate reductase activity such as from a Mycobacterium smegmatis (see Genbank Accession No.
  • ABK71854.1 SEQ ID NO: 3
  • a Mycobacterium massiliense see Genbank Accession No. EI VI 1143.1, SEQ ID NO: 6
  • a Segniliparus rotundus see Genbank Accession No. ADG98140.1, SEQ ID NO: 7
  • a phosphopantetheine transferase enhancer e.g., encoded by a sfp (Genbank Accession No. CAA44858.1, SEQ ID NO:21) gene irom Bacillus subtilis or npt (Genbank Accession No.
  • cadaverine is synthesized from the central precursor glutarate semialdehyde by conversion of glutarate semialdehyde to pentanedial by a polypeptide having carboxylate reductase activity classified, for example, under EC 1.2.99.6 such as from a Segniliparus rotundus (see Genbank Accession No.
  • ADG98140.1, SEQ ID NO: 7 in combination with a phosphopantetheine transferase enhancer (e.g., encoded by a sfp (Genbank Accession No. CAA44858.1, SEQ ID NO:21) gene from Bacillus subtilis or npt (Genbank Accession No. ABI83656.1 , SEQ ID NO:22) gene from Nocardia), or the gene product of GriC & GriD (Suzuki et ah, J. Antibiot., 2007, 60(6), 380 - 387); followed by conversion to 5-aminopentanal by a polypeptide having ⁇ -transaminase activity classified, for example, under EC 2.6.1.- such as
  • Chromobacterium violaceum see Genbank Accession No. AAQ59697.1 , SEQ ID NO:
  • Rhodobacter sphaeroides see Genbank Accession No. ABA81135.1, SEQ ID NO:
  • Genbank Accession No. 11 an Escherichia coli (see Genbank Accession No. AAA57874.1, SEQ ID NO: 12), or a Vibrio fluvialis (see Genbank Accession No. AEA39183.1, SEQ ID NO: 13); followed by conversion to cadaverine by a polypeptide having ⁇ -transaminase activity classified, for example, under EC 2.6.1.- such as 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48, or EC 2.6.1.82 such as from a Chromobacterium violaceum (see Genbank Accession No.
  • cadaverine is synthesized from the central precursor 1,5- pentanediol by conversion of 1,5-pentanediol to 5-hydroxypentanal by a polypeptide having alcohol dehydrogenase activity classified, for example, under EC 1.1.1.- (e.g., EC 1.1.1.1, EC 1.1.1.2, EC 1.1.1.21, or EC 1.1.1.184) such as the gene product of YMR318C (Genbank Accession No. CAA90836.1) or YqhD (from E. coli, GenBank Accession No.
  • AAA69178.1 (Liu et al, Microbiology, 2009, 155, 2078 - 2085; Larroy et al, 2002, Biochem J., 361(Pt 1), 163 - 172; Jarboe, 2Q ⁇ ⁇ , Appl. Microbiol. BiotechnoL, 89(2), 249 - 257) or the protein having GenBank Accession No.
  • CAA81612.1 followed by conversion of 5-oxopentanal to 5-aminopentanol by a polypeptide having ⁇ - transaminase activity classified, for example, under EC 2.6.1.- such as 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48, or EC 2.6.1.82 such as from a Chromobacterium violaceum (see Genbank Accession No. AAQ59697.1 , SEQ ID NO: 8), a Pseudomonas aeruginosa (see Genbank Accession No. AAG08191.1, SEQ ID NO: 9), a Pseudomonas syringae (see Genbank Accession No.
  • AEA39183.1 SEQ ID NO: 13
  • a polypeptide having alcohol dehydrogenase activity classified, for example, under EC 1.1.1.- (e.g., EC 1.1.1.1, EC 1.1.1.2, EC 1.1.1.21, or EC 1.1.1.184)
  • EC 1.1.1.- e.g., EC 1.1.1.1, EC 1.1.1.2, EC 1.1.1.21, or EC 1.1.1.184
  • YMR318C Genebank Accession No. CAA90836.1
  • YqhD from E. coli, GenBank Accession No.
  • AAA69178.1 (Liu et al., Microbiology, 2009, 155, 2078 - 2085; Larroy et al., 2002, Biochem J, 361(Pt 1), 163 - 172; Jarboe, 2011, Appl. Microbiol. BiotechnoL, 89(2), 249 - 257) or the protein having GenBank Accession No.
  • 1,5 pentanediol is synthesized from the central precursor 5-hydroxypentanoate by conversion of 5-hydroxypentanoate to 5-hydroxypentanal by a polypeptide having carboxylate reductase activity classified, for example, under EC 1.2.99.6 such as from a Mycobacterium marinum (see Genbank Accession No.
  • ACC40567.1 SEQ ID NO: 2
  • a Mycobacterium smegmatis see Genbank Accession No. ABK71854.1, SEQ ID NO: 3
  • a Mycobacterium smegmatis see Genbank Accession No. ABK75684.1, SEQ ID NO: 5
  • a Mycobacterium massiliense see Genbank Accession No. EI VI 1143.1, SEQ ID NO: 6
  • a Segniliparus rotundus see Genbank Accession No. ADG98140.1, SEQ ID NO: 7
  • a phosphopantetheine transferase enhancer e.g., encoded by a sfp (Genbank Accession No.
  • CAA44858.1 SEQ ID NO:21
  • gene irom Bacillus subtilis or npt (Genbank Accession No. ABI83656.1, SEQ ID NO:22) gene from Nocardia), or the gene product of GriC & GriD (Suzuki et al., J.
  • AAA69178.1 (see, e.g., Liu et al., Microbiology, 2009, 155, 2078 - 2085; Larroy et al., 2002, Biochem J, 361(Pt 1), 163 - 172; or Jarboe, 2011, Appl. Microbiol. Biotechnol, 89(2), 249 - 257) or the protein having GenBank Accession No. CAA81612.1 (from Geobacillus stearothermophilus). See, FIG. 8.
  • pentanoyl-CoA can be converted to pentanoic acid pentyl ester using a polypeptide having alcohol O-acetyltransf erase activity classified, for example, under EC 2.3.1.-(84) such as the gene product of Ehtl (Genbank Accession No: CAA85138.1, SEQ ID NO: 26); followed by conversion to pentanoic acid 5-hydroxy pentyl ester and/or 5-hydroxypentanoic acid 5-hydroxypentyl ester using a polypeptide having monooxygenase activity classified, for example, under EC 1.14.14.- or EC 1.14.15.- (1,3).
  • a polypeptide having monooxygenase activity can be, for example, from the CYP153A family, the CYP52A3 (Genbank Accession No:
  • BAA00371.1, SEQ ID NO: 29) family or the alkB family such as the gene product of alkB GT from Pseudomonas putida (Genbank Accession No. CAB51047.1, SEQ ID NO: 28); followed by conversion of pentanoic acid 5-hydroxy pentyl ester and/or 5- hydroxypentanoic acid 5-hydroxypentyl to 1,5-pentanediol using a polypeptide having esterase activity classified, for example, under EC 3.1.1. -(1,6) such as the gene product ofEstC (see GenBank Accession No. AAC60471.2, SEQ ID NO: 27). See FIG. 8.
  • the cultivation strategy entails achieving an aerobic, anaerobic, micro-aerobic, or mixed oxygen/denitrification cultivation condition.
  • Enzymes characterized in vitro as being oxygen sensitive require a micro-aerobic cultivation strategy maintaining a very low dissolved oxygen concentration (See, for example,
  • the cultivation strategy entails nutrient limitation such as nitrogen, phosphate or oxygen limitation.
  • a final electron acceptor other than oxygen such as nitrates can be utilized.
  • a cell retention strategy using, for example, ceramic membranes can be employed to achieve and maintain a high cell density during either fed-batch or continuous fermentation.
  • the principal carbon source fed to the fermentation in the synthesis of one or more C5 building blocks can derive from biological or non-biological feedstocks.
  • the biological feedstock can be or can derive from, monosaccharides, disaccharides, lignocellulose, hemicellulose, cellulose, lignin, levulinic acid and formic acid, triglycerides, glycerol, fatty acids, agricultural waste, condensed distillers' solubles, or municipal waste.
  • fermentable sugars such as monosaccharides and disaccharides derived from cellulosic, hemicellulosic, cane and beet molasses, cassava, corn and other agricultural sources has been demonstrated for several microorganism such as Escherichia coli, Corynebacterium glutamicum and Lactobacillus delbrueckii and Lactococcus lactis (see, e.g., Hermann et al, J. BiotechnoL, 2003, 104: 155 - 172; Wee et al., Food TechnoL BiotechnoL, 2006, 44(2): 163 - 172; Ohashi et al., J. Bioscience and Bioengineering, 1999, 87(5):647 - 654).
  • microorganism such as Escherichia coli, Corynebacterium glutamicum and Lactobacillus delbrueckii and Lactococcus lactis
  • the non-biological feedstock can be or can derive from natural gas, syngas, CO2/H2, methanol, ethanol, benzoate, non-volatile residue (NVR) or a caustic wash waste stream from cyclohexane oxidation processes, or terephthalic acid / isophthalic acid mixture waste streams.
  • the host microorganism is a prokaryote.
  • the prokaryote can be a bacterium from the genus Escherichia such as Escherichia coli; from the genus Clostridia such as Clostridium ljungdahlii, Clostridium autoethanogenum or Clostridium kluyveri; from the genus Corynebacteria such as Cory neb acterium glutamicum; from the genus Cupriavidus such as Cupriavidus necator or Cupriavidus metallidurans; from the genus Pseudomonas such as Pseudomonas fluorescens,
  • Pseudomonas putida or Pseudomonas oleavorans from the genus Delftia such as Delftia acidovorans; from the genus Bacillus such as Bacillus subtillis; from the genus
  • the host microorganism is a eukaryote.
  • the eukaryote can be a filamentous fungus, e.g., one from the genus Aspergillus such as Aspergillus niger.
  • the eukaryote can be a yeast, e.g., one from the genus Saccharomyces such as Saccharomyces cerevisiae; from the genus Pichia such as Pichia pastoris; or from the genus Yarrowia such as Yarrowia lipolytica; from the genus Issatchenkia such as Issathenkia orientalis; from the genus Debaryomyces such as Debaryomyces hansenii; from the genus Arxula such as Arxula adenoinivorans; or from the genus Kluyveromyces such as Kluyveromyces lactis.
  • Such eukaryotes also can be a source of genes to construct recombinant host cells described herein that are capable of producing one or more C5 building blocks.
  • the present document provides methods involving less than all the steps described for all the above pathways. Such methods can involve, for example, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or more of such steps. Where less than all the steps are included in such a method, the first, and in some embodiments the only, step can be any one of the steps listed.
  • recombinant hosts described herein can include any combination of the above enzymes such that one or more of the steps, e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more of such steps, can be performed within a recombinant host.
  • This document provides host cells of any of the genera and species listed and genetically engineered to express one or more (e.g., two, three, four, five, six, seven, eight, nine, 10, 11, 12 or more) recombinant forms of any of the enzymes recited in the document.
  • the host cells can contain exogenous nucleic acids encoding enzymes catalyzing one or more of the steps of any of the pathways described herein.
  • one or more steps in a pathway that use an enzyme with specificity for NADH can be replaced with an enzyme having similar or identical activity and specificity for NADPH.
  • one or more steps in a pathway that use an enzyme with specificity for NADPH can be replaced with an enzyme having similar or identical activity and specificity for NADH.
  • the enzymes in the pathways outlined herein are the result of enzyme engineering via non-direct or rational enzyme design approaches with aims of improving activity, improving specificity, reducing feedback inhibition, reducing repression, improving enzyme solubility, changing stereo-specificity, or changing co- factor specificity.
  • the enzymes in the pathways outlined here can be gene dosed, i.e., overexpressed, into the resulting genetically modified organism via episomal or chromosomal integration approaches.
  • genome-scale system biology techniques such as Flux
  • Balance Analysis can be utilized to devise genome scale attenuation or knockout strategies for directing carbon flux to a C5 building block.
  • Attenuation strategies include, but are not limited to; the use of transposons, homologous recombination (double cross-over approach), mutagenesis, enzyme inhibitors and RNAi interference.
  • fluxomic, metabolomic and transcriptomal data can be utilized to inform or support genome-scale system biology techniques, thereby devising genome scale attenuation or knockout strategies in directing carbon flux to a C5 building block.
  • the host microorganism's tolerance to high concentrations of a C5 building block can be improved through continuous cultivation in a selective environment.
  • the host microorganism's endogenous biochemical network can be attenuated or augmented to (1) ensure the intracellular availability of acetyl-CoA and propanoyl-CoA, (2) create a NADH or NADPH imbalance that may be balanced via the formation of one or more C5 building blocks, (3) prevent degradation of central metabolites, central precursors leading to and including one or more C5 building blocks and/or (4) ensure efficient efflux from the cell.
  • endogenous enzymes catalyzing the hydrolysis of propionoyl-CoA and acetyl-CoA such as short-chain length polypeptides having thioesteras activity can be attenuated in the host organism.
  • endogenous enzymes consuming propanoyl-CoA to succinyl-CoA via the methylcitrate cycle such as a polypeptide having methylcitrate synthase activity can be attenuated in the host organism (Bramer & Steinbuchel, 2001, Microbiology, 147: 2203 - 2214).
  • a feedback-resistant polypeptide having threonine deaminase activity can be genetically engineered into the host organism (Tseng et ah, Microbial Cell Factories, 2010, 9:96).
  • one or more endogenous polypeptides having ⁇ - ketothiolases activity catalyzing the condensation of only acetyl-CoA to acetoacetyl- CoA such as the endogenous gene products ofAtoB or phaA can be attenuated.
  • an endogenous polypeptide having phosphotransacetyla.se activity generating acetate such as pta can be attenuated (Shen et ⁇ ., ⁇ . Environ. Microbiol, 2011, 77(9):2905-2915).
  • an endogenous gene in an acetate synthesis pathway encoding a polypeptide having acetate kinase activity, such as ack can be attenuated.
  • an endogenous gene encoding an enzyme that catalyzes the degradation of pyruvate to lactate such as a polypeptide having lactate dehydrogenase activity encoded by IdhA can be attenuated (Shen et al, 2011, supra).
  • endogenous genes encoding enzymes such as a polypeptide having menaquinol-fumarate oxidoreductase activity, that catalyze the degradation of phophoenolpyruvate to succinate such as frdBC can be attenuated (see, e.g., Shen et al., 2011, supra).
  • an endogenous gene encoding an enzyme that catalyzes the degradation of acetyl-CoA to ethanol such as the polypeptide having alcohol dehydrogenase activity encoded by adhE can be attenuated (Shen et al. , 2011 , supra).
  • a recombinant polypeptide having formate dehydrogenase activity can be overexpressed in the host organism (Shen et al, 2011, supra).
  • a polypeptide having transhydrogenase activity dissipating the cofactor imbalance can be attenuated.
  • an endogenous gene encoding an enzyme that catalyzes the degradation of pyruvate to ethanol such as polypeptide having pyruvate
  • decarboxylase activity can be attenuated.
  • an endogenous gene encoding an enzyme that catalyzes the generation of isobutanol such as a polypeptide having 2-oxoacid decarboxylase activity can be attenuated.
  • a recombinant polypeptide having acetyl-CoA synthetase activity such as the gene product of acs can be overexpressed in the microorganism (Satoh et al, J. Bioscience and Bio engineering, 2003, 95(4):335 - 341).
  • carbon flux can be directed into the pentose phosphate cycle to increase the supply of NADPH by attenuating an endogenous polypeptide having glucose-6-phosphate isomerase activity (EC 5.3.1.9).
  • carbon flux can be redirected into the pentose phosphate cycle to increase the supply of NADPH by overexpression a polypeptide having 6- phosphogluconate dehydrogenase activity and/or a polypeptide having transketolase activity (Lee et al., 2003, Biotechnology Progress, 19(5), 1444 - 1449).
  • a gene such as UdhA encoding a polypeptide having puridine nucleotide transhydrogenase activity can be overexpressed in the host organisms (Brigham et al., Advanced Biofuels and Bioproducts, 2012, Chapter 39, 1065 - 1090).
  • a recombinant polypeptide having glyceraldehyde-3- phosphate-dehydrogenase activity such as GapN can be overexpressed in the host organisms (Brigham et al, 2012, supra).
  • a recombinant polypeptide having malic enzyme activity such as maeA or maeB can be overexpressed in the host organisms (Brigham et al, 2012, supra).
  • a recombinant polypeptide having glucose-6-phosphate dehydrogenase activity such as zwf can be overexpressed in the host organisms (Lim et al., J. Bioscience and Bioengineering, 2002, 93(6), 543 - 549).
  • a recombinant polypeptide having fructose 1,6 diphosphatase activity such as fbp can be overexpressed in the host organisms (Becker et al., J. BiotechnoL, 2007, 132:99 - 109).
  • endogenous polypeptide having triose phosphate isomer ase activity (EC 5.3.1.1) can be attenuated.
  • dehydrogenase activity such as the gene product of gdh can be overexpressed in the host organism (Satoh et ah, J. Bioscience and Bioengineering, 2003, 95(4):335 - 341).
  • endogenous enzymes facilitating the conversion of NADPH to NADH can be attenuated, such as the NADH generation cycle that may be generated via inter-conversion of polypeptides having glutamate dehydrogenase activity classified under EC 1.4.1.2 (NADH-specific) and EC 1.4.1.4 (NADPH-specific).
  • an endogenous polypeptide having glutamate having glutamate
  • dehydrogenase activity (EC 1.4.1.3) that utilizes both NADH and NADPH as co-factors can be attenuated.
  • a membrane-bound polypeptide having cytochrome P450 activity such as CYP4F3B can be solubilized by only expressing the cytosolic domain and not the N-terminal region that anchors the P450 to the endoplasmic reticulum (see, for example, Scheller et al, J. Biol. Chem., 1994, 269(17): 12779-12783).
  • a membrane-bound polypeptide having enoyl-CoA reductase activity can be solubilized via expression as a fusion protein to a small soluble protein such as a maltose binding protein (Gloerich et al, FEBS Letters, 2006, 580, 2092 - 2096).
  • a maltose binding protein Gloerich et al, FEBS Letters, 2006, 580, 2092 - 2096.
  • polyhydroxyalkanoates the endogenous polypeptide having polyhydroxyalkanoate synthase activity can be attenuated in the host strain.
  • a recombinant polypeptide having propionyl-CoA synthetase activity such as the gene product of PrpE-RS can be overexpressed in the microorganism (Rajashekhara & Watanabe, FEBS Letters, 2004, 556: 143 - 147).
  • a polypeptide having L-alanine dehydrogenase activity can be overexpressed in the host to regenerate L-alanine from pyruvate as an amino donor for co-transaminase reactions.
  • a polypeptide having L-glutamate dehydrogenase activity, a polypeptide having L-glutamine synthetase activity, or a polypeptide having glutamate synthase activity can be overexpressed in the host to regenerate L-glutamate from 2- oxoglutarate as an amino donor for co-transaminase reactions.
  • enzymes such as polypeptide having pimeloyl-CoA dehydrogenase activity classified under, EC 1.3.1.62; a polypeptide having acyl-CoA dehydrogenase activity classified, for example, under EC 1.3.8.7 or EC 1.3.8.1; and/or a polypeptide having glutaryl-CoA dehydrogenase activity classified, for example, under EC 1.3.8.6 that degrade central metabolites and central precursors leading to and including C5 building blocks can be attenuated.
  • endogenous enzymes activating C5 building blocks via Coenzyme A esterification such as polypeptides having CoA-ligase activity (e.g., a pimeloyl-CoA synthetase) classified under, for example, EC 6.2.1.14 can be attenuated.
  • polypeptides having CoA-ligase activity e.g., a pimeloyl-CoA synthetase
  • EC 6.2.1.14 can be attenuated.
  • the efflux of a C5 building block across the cell membrane to the extracellular media can be enhanced or amplified by genetically engineering structural modifications to the cell membrane or increasing any associated transporter activity for a C5 building block.
  • the efflux of cadaverine can be enhanced or amplified by overexpressing broad substrate range multidrug transporters such as Bit from Bacillus subtilis (Woolridge et al., 1997, J. Biol. Chem., 272(14):8864 - 8866); AcrB and AcrD from Escherichia coli (Elkins & Nikaido, 2002, J.
  • broad substrate range multidrug transporters such as Bit from Bacillus subtilis (Woolridge et al., 1997, J. Biol. Chem., 272(14):8864 - 8866); AcrB and AcrD from Escherichia coli (Elkins & Nikaido, 2002, J.
  • the efflux of 5-aminopentanoate and cadaverine can be enhanced or amplified by overexpressing the solute transporters such as the lysE transporter from Corynebacterium glutamicum (Bellmann et al, 2001, Microbiology, 147, 1765 - 1774).
  • solute transporters such as the lysE transporter from Corynebacterium glutamicum (Bellmann et al, 2001, Microbiology, 147, 1765 - 1774).
  • the efflux of glutaric acid can be enhanced or amplified by overexpressing a dicarboxylate transporter such as the SucE transporter from Corynebacterium glutamicum (Huhn et al, Appl. Microbiol. & Biotech., 89(2), 327 - 335).
  • a dicarboxylate transporter such as the SucE transporter from Corynebacterium glutamicum (Huhn et al, Appl. Microbiol. & Biotech., 89(2), 327 - 335).
  • one or more C5 building blocks can be produced by providing a host microorganism and culturing the provided microorganism with a culture medium containing a suitable carbon source as described above.
  • the culture media and/or culture conditions can be such that the microorganisms grow to an adequate density and produce a C5 building block efficiently.
  • any method can be used such as those described elsewhere (Manual of Industrial Microbiology and Biotechnology, 2 nd Edition, Editors: A. L. Demain and J. E. Davies, ASM Press; and Principles of Fermentation Technology, P. F. Stanbury and A. Whitaker, Pergamon).
  • a large tank e.g., a 100 gallon, 200 gallon, 500 gallon, or more tank
  • an appropriate culture medium is inoculated with a particular microorganism.
  • the microorganism is incubated to allow biomass to be produced.
  • the broth containing the microorganisms can be transferred to a second tank.
  • This second tank can be any size.
  • the second tank can be larger, smaller, or the same size as the first tank.
  • the second tank is larger than the first such that additional culture medium can be added to the broth from the first tank.
  • the culture medium within this second tank can be the same as, or different from, that used in the first tank.
  • the microorganisms can be incubated to allow for the production of a C5 building block.
  • any method can be used to isolate C5 building blocks.
  • C5 building blocks can be recovered selectively from the fermentation broth via adsorption processes.
  • glutaric acid and 5- aminopentanoic acid the resulting eluate can be further concentrated via evaporation, crystallized via evaporative and/or cooling crystallization, and the crystals recovered via centrifugation.
  • distillation may be employed to achieve the desired product purity.
  • a nucleotide sequence encoding an N-terminal His-tag was added to the genes from Chromobacterium violaceum and Rhodobacter sphaeroides encoding the co- transaminases of SEQ ID NOs: 8 and 10 respectively (see FIG. 10) such that N-terminal HIS tagged co-transaminases could be produced.
  • Each of the resulting modified genes was cloned into a pET21a expression vector under control of the T7 promoter and each expression vector was transformed into a BL21 [DE3] E. coli host. The resulting recombinant E.
  • coli strains were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 16 °C using 1 mM IPTG.
  • the pellet from each induced shake flask culture was harvested via centrifugation. Each pellet was resuspended and lysed via sonication. The cell debris was separated from the supernatant via centrifugation and the cell free extract was used immediately in enzyme activity assays.
  • Each enzyme activity assay reaction was initiated by adding cell free extract of the c -transaminase gene product or the empty vector control to the assay buffer containing the 5-aminopentanoate and incubated at 25°C for 4 h, with shaking at 250 rpm.
  • the formation of L-alanine from pyruvate was quantified via RP- HPLC.
  • Enzyme activity in the forward direction i.e., glutarate semialdehyde to 5- aminopentanoate
  • Each enzyme activity assay reaction was initiated by adding a cell free extract of the co-transaminase gene product or the empty vector control to the assay buffer containing the glutarate semialdehyde and incubated at 25°C for 4 h, with shaking at 250 rpm. The formation of pyruvate was quantified via RP-HPLC.
  • the gene product of SEQ ID NO 10 accepted glutarate semialdehyde as substrate as confirmed against the empty vector control. See FIG. 19. The reversibility of the co- transaminase activity was confirmed, demonstrating that the co-transaminases of SEQ ID NO 8, and SEQ ID NO 10 accepted glutarate semialdehyde as substrate and synthesized 5-aminopentanoate as a reaction product.
  • a nucleotide sequence encoding a His-tag was added to the genes from
  • Mycobacterium marinum Mycobacterium smegmatis, Segniliparus rugosus,
  • E. coli host along with the expression vectors from Example 3.
  • Each resulting recombinant E. coli strain was cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 37°C using an auto-induction media.
  • Enzyme activity i.e., 5-hydroxypentanoate to 5-hydroxypentanal
  • Each enzyme activity assay reaction was initiated by adding purified
  • the modified genes were cloned into a pET21a expression vector under the T7 promoter. Each expression vector was transformed into a BL21 [DE3] E. coli host. Each resulting recombinant E. coli strain were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 16°C using 1 mM IPTG.
  • the pellet from each induced shake flask culture was harvested via centrifugation. Each pellet was resuspended and lysed via sonication. The cell debris was separated from the supernatant via centrifugation and the cell free extract was used immediately in enzyme activity assays.
  • Each enzyme activity assay reaction was initiated by adding cell free extract of the co-transaminase gene product or the empty vector control to the assay buffer containing the 5-aminopentanol and then incubated at 25 °C for 4 h, with shaking at 250 rpm. The formation of L-alanine was quantified via RP-HPLC.
  • the modified genes were cloned into a pET21a expression vector under the T7 promoter. Each expression vector was transformed into a BL21 [DE3] E. coli host. Each resulting recombinant E. coli strain were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 16°C using 1 mM IPTG.
  • the pellet from each induced shake flask culture was harvested via centrifugation. Each pellet was resuspended and lysed via sonication. The cell debris was separated from the supernatant via centrifugation and the cell free extract was used immediately in enzyme activity assays.
  • Each enzyme activity assay reaction was initiated by adding cell free extract of the co-transaminase gene product or the empty vector control to the assay buffer containing the cadaverine and then incubated at 25 °C for 4 h, with shaking at 250 rpm. The formation of L-alanine was quantified via RP-HPLC.
  • the gene products of SEQ ID NOs: 8 - 10 and 12 accepted cadaverine as substrate as confirmed against the empty vector control (see FIG. 20) and synthesized 5- aminopentanal as reaction product. Given the reversibility of the co-transaminase activity (see Example 1), it can be concluded that the gene products of SEQ ID NOs: 8 - 10 and 12 accept 5-aminopentanal as substrate and form cadaverine.
  • Each enzyme activity assay reaction was initiated by adding a cell free extract of the c -transaminase or the empty vector control to the assay buffer containing the N5-acetyl-l,5-diaminopentane then incubated at 25 °C for 4 h, with shaking at 250 rpm.
  • the formation of L-alanine was quantified via RP- HPLC.
  • the gene product of SEQ ID NOs: 8, 10 accepted N5 -acetyl- 1,5 -diaminopentane as substrate as confirmed against the empty vector control (see FIG. 15) and synthesized N5-acetyl-5-aminopentanal as reaction product.
  • the N-terminal His-tagged carboxylate reductase of SEQ ID NO 7 was assayed using glutarate semialdehyde as substrate.
  • the enzyme activity assay reaction was initiated by adding purified carboxylate reductase and phosphopantetheine transferase or the empty vector control to the assay buffer containing the glutarate semialdehyde and then incubated at room temperature for 20 min.
  • the consumption of NADPH was monitored by absorbance at 340 nm.
  • the N-terminal His-tagged carboxylate reductase of SEQ ID NOs 2, 3, 6 and 7 was assayed using glutarate semialdehyde as substrate.
  • the enzyme activity assay reaction was initiated by adding purified carboxylate reductase and phosphopantetheine transferase or the empty vector control to the assay buffer containing the pentanoate and then incubated at room temperature for 20 min.
  • the consumption of NADPH was monitored by absorbance at 340 nm.
  • the enzyme only control without pentanoate demonstrated low base line consumption of NADPH. See FIG. 12.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des voies biochimiques pour la production de 5-hydroxypentanoate de méthyle et de pentanoate de pentyle faisant appel à une ou plusieurs enzymes parmi une O-méthyltransférase d'acide gras, une O-acétyltransférase d'alcool, et une mono-oxygénase, ainsi que des hôtes de recombinaison exprimant une ou plusieurs de ces enzymes exogènes. Les 5-hydroxypentanoates de méthyle et les pentanoates de pentyle peuvent alors être convertis par voie enzymatique en acide glutarique, 5-aminopentanoate, 5-hydroxypentanoate, cadavérine, ou 1,5-pentanediol.
PCT/US2015/036074 2014-06-16 2015-06-16 Procédés, réactifs et cellules pour la biosynthèse de composés WO2015195695A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201580043260.XA CN106795536A (zh) 2014-06-16 2015-06-16 用于生物合成化合物的方法、试剂和细胞
EP15731806.4A EP3155110A1 (fr) 2014-06-16 2015-06-16 Procédés, réactifs et cellules pour la biosynthèse de composés
BR112016029365A BR112016029365A2 (pt) 2014-06-16 2015-06-16 métodos, reagentes e células para biossíntese de compostos

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462012666P 2014-06-16 2014-06-16
US201462012659P 2014-06-16 2014-06-16
US201462012604P 2014-06-16 2014-06-16
US62/012,666 2014-06-16
US62/012,659 2014-06-16
US62/012,604 2014-06-16

Publications (1)

Publication Number Publication Date
WO2015195695A1 true WO2015195695A1 (fr) 2015-12-23

Family

ID=53487463

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2015/036050 WO2015195678A1 (fr) 2014-06-16 2015-06-16 Procédés, réactifs et cellules pour la biosynthèse de composés
PCT/US2015/036074 WO2015195695A1 (fr) 2014-06-16 2015-06-16 Procédés, réactifs et cellules pour la biosynthèse de composés
PCT/US2015/036057 WO2015195682A1 (fr) 2014-06-16 2015-06-16 Procédés, réactifs et cellules pour la biosynthèse de composés

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2015/036050 WO2015195678A1 (fr) 2014-06-16 2015-06-16 Procédés, réactifs et cellules pour la biosynthèse de composés

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2015/036057 WO2015195682A1 (fr) 2014-06-16 2015-06-16 Procédés, réactifs et cellules pour la biosynthèse de composés

Country Status (5)

Country Link
US (4) US9816117B2 (fr)
EP (3) EP3155108A1 (fr)
CN (3) CN106795535A (fr)
BR (3) BR112016029391A2 (fr)
WO (3) WO2015195678A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
CN106795535A (zh) * 2014-06-16 2017-05-31 英威达技术有限责任公司 用于生物合成化合物的方法，试剂和细胞
CN107602399B (zh) * 2016-07-11 2020-09-25 江西东邦药业有限公司 一种脑啡肽酶抑制剂中间体的制备方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3728180A4 (fr) * 2017-12-21 2021-07-28 Performance Polyamides, SAS Procédé de préparation de diamines primaires au moyen d'une réaction de couplage par électrolyse de kolbe
CN111936623B (zh) * 2018-03-30 2023-08-25 英威达纺织（英国）有限公司 用于生物合成制造庚二酸的材料与方法和合成多肽的利用
US20190352674A1 (en) 2018-05-02 2019-11-21 Invista North America S.A.R.L. Materials and methods for controlling limitation conditions in product biosynthesis for non-phb generating species of the genera ralstonia or cupriavidus and organisms related thereto
CN112812985B (zh) * 2020-11-11 2023-01-10 新疆阜丰生物科技有限公司 一种提高谷氨酰胺发酵产酸的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361769B1 (en) * 2009-11-16 2013-01-29 U.S. Department Of Energy Regioselective alkane hydroxylation with a mutant CYP153A6 enzyme
US20130183728A1 (en) * 2011-12-16 2013-07-18 Invista North America S.A R.L. METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE
WO2014105793A1 (fr) * 2012-12-31 2014-07-03 Invista North America S.A.R.L. Procédés de production d'agents chimiques à 7 atomes de carbone à partir d'acides gras à longue chaîne par clivage oxydatif

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2439513A (en) 1945-11-30 1948-04-13 Du Pont Adipic acid process
US2557282A (en) 1949-03-31 1951-06-19 Du Pont Adipic acid process
US2791566A (en) 1953-09-16 1957-05-07 Ici Ltd Catalyst recovery process
US2840607A (en) 1956-02-20 1958-06-24 Union Oil Co Separation of dibasic acids
US2971010A (en) 1958-06-26 1961-02-07 Du Pont Production of dicarboxylic acid anhydrides
NL255708A (fr) 1959-09-08
US3338959A (en) 1962-08-22 1967-08-29 Du Pont Process for separation and recovery of glutaric, succinic, and adipic acids
US3365490A (en) 1966-08-05 1968-01-23 Du Pont Process for the production of dicarboxylic acids
US3719561A (en) 1966-08-26 1973-03-06 Kyowa Hakko Kogyo Kk Process for producing diaminopimelic acid
US3515751A (en) 1967-09-25 1970-06-02 Firestone Tire & Rubber Co Process for oxidation of cyclohexane
US4058555A (en) 1969-07-18 1977-11-15 El Paso Products Company Process for the purification of mixed acids
DE19706023A1 (de) 1997-02-17 1998-08-20 Bayer Ag Abbau von biologisch abbaubaren Polymeren mit Enzymen
US6372939B1 (en) 2000-11-16 2002-04-16 E.I. Du Pont De Nemours And Company Production of 6-aminocaproic acid
US6703529B1 (en) 2002-09-12 2004-03-09 E. I. Du Pont De Nemours And Company Process for oxidation of cyclohexane
US8110670B2 (en) 2006-05-19 2012-02-07 Ls9, Inc. Enhanced production of fatty acid derivatives
EP2041267A4 (fr) 2006-07-06 2009-09-02 Integrated Genomics Inc Compositions et procédés pour augmenter l'utilisation du glycerol
JP5449142B2 (ja) 2007-06-01 2014-03-19 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング メタクリル酸又はメタクリルエステルの製造方法
FR2921364B1 (fr) 2007-09-20 2009-11-06 Arkema France Procede de coproduction de 7-oxoheptanoate de methyle et d'acide undecylenique a partir d'acide ricinoleique
US8673599B2 (en) 2008-03-11 2014-03-18 Dsm Ip Assets B.V. Preparation of 6-aminocaproic acid from 5-formylvaleric acid
JP2011512868A (ja) 2008-03-11 2011-04-28 ディーエスエム アイピー アセッツ ビー．ブイ． アジピン酸（エステルまたはチオエステル）の合成
EP2265709B1 (fr) 2008-03-27 2017-11-08 Genomatica, Inc. Microorganismes pour la production d'acide adipique et autres composés
WO2009121066A1 (fr) 2008-03-28 2009-10-01 The Regents Of The University Of California Production d’acides dicarboxyliques utilisant des polycétide synthases
US8389252B2 (en) 2008-05-12 2013-03-05 Butamax(Tm) Advanced Biofuels Llc Yeast strain for production of four carbon alcohols
CN102027109B (zh) 2008-05-16 2016-01-06 Reg生命科学有限责任公司 产生碳氢化合物的方法和组合物
US20100035309A1 (en) 2008-08-06 2010-02-11 Luca Technologies, Inc. Analysis and enhancement of metabolic pathways for methanogenesis
JP5770099B2 (ja) 2008-12-12 2015-08-26 メタボリックス，インコーポレイテッド ポリ（５ｈｖ）および５炭素化合物を製造するための環境に優しい方法および組成物
MY153590A (en) 2008-12-12 2015-02-26 Celexion Llc Biological synthesis of difunctional alkanes from alpha ketoacids
EP2376421A4 (fr) 2008-12-18 2012-12-12 Invista Tech Sarl Dérivés de sous-produits d'un procédé d'oxydation de cyclohexane et procédés d'utilisation de ceux-ci
US20120156737A1 (en) 2009-03-11 2012-06-21 Dsm Ip Assets B.V. Preparation of alpha-ketopimelic acid
ES2749423T3 (es) 2009-05-07 2020-03-20 Genomatica Inc Microorganismos y métodos para la biosíntesis de adipato, hexametilendiamina y ácido 6-aminocaproico
AU2010248831A1 (en) 2009-05-15 2011-11-24 Genomatica, Inc. Organisms for the production of cyclohexanone
US20100298612A1 (en) 2009-05-22 2010-11-25 Codexis, Inc. Engineered biosynthesis of fatty alcohols
SG176970A1 (en) 2009-07-02 2012-02-28 Verdezyne Inc Biological methods for preparing adipic acid
TW201127961A (en) 2009-09-11 2011-08-16 Dsm Ip Assets Bv Preparation of a compound comprising an amine group from an alpha-keto acid
US20120231512A1 (en) 2009-09-11 2012-09-13 Dsm Ip Assets B.V. Preparation of alpha-ketopimelic acid
WO2012031910A2 (fr) 2010-09-10 2012-03-15 Dsm Ip Assets B.V. Procédé de préparation d'acide alpha-cétopimélique par élongation c1
WO2012071439A1 (fr) 2010-11-22 2012-05-31 The Regents Of The University Of California Cellules hôtes et procédés pour produire des diacides
CA2823404C (fr) 2011-01-05 2021-07-06 Verdezyne, Inc. Procedes biologiques pour preparer de l'acide adipique
BR112013025226A2 (pt) 2011-04-01 2018-09-11 Genomatica Inc micro-organismos para produzir ácido metacrílico e ésteres de metacrilato e métodos relacionados a eles
WO2012174451A1 (fr) 2011-06-17 2012-12-20 Invista Technologies S.A.R.L. Utilisation d'hydrolases pour augmenter la teneur en monomères dans un flux de déchets
MY161761A (en) 2011-06-17 2017-05-15 Invista Tech Sarl Methods of making nylon intermediates from glycerol
AU2012273093A1 (en) 2011-06-22 2013-05-02 Genomatica, Inc. Microorganisms for producing 6-aminocaproic acid
JP2014525741A (ja) 2011-06-30 2014-10-02 インビスタ テクノロジーズ エス．アー．エール．エル． ナイロン−７、ナイロン−７，７、およびポリエステルを生産するための生物変換方法
WO2013028519A1 (fr) 2011-08-19 2013-02-28 Genomatica, Inc. Microorganismes et procédés de fabrication de 2,4-pentadiénoate, de butadiène, de propylène, de 1,3-butanediol et d'alcools associés
EP2785848A2 (fr) 2011-12-02 2014-10-08 INVISTA Technologies S.à.r.l. Procédés de biosynthèse du 1,3-butadiène
CN104220601A (zh) * 2011-12-16 2014-12-17 英威达技术有限责任公司 经与碳储存相关的CoA 依赖性碳链延长制备6 碳化学品的方法
US9102960B2 (en) 2011-12-16 2015-08-11 Invista North America S.á.r.l. Methods of producing 6-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
JP2015500663A (ja) 2011-12-21 2015-01-08 インビスタ テクノロジーズ エス．アー．エール．エル． ナイロン−７、ナイロン−７，７、およびポリエステルを生産するための生物変換方法
EP2647718A3 (fr) 2012-04-06 2014-12-24 Metabolic Explorer Procédé de production de 5-aminopentanoate en utilisant un micro-organisme recombinant
US9890405B2 (en) 2012-08-23 2018-02-13 Bioamber Inc. Recombinant bacterial cells producing (S)-2-amino-6-hydroxypimelate
US9790525B2 (en) 2012-12-14 2017-10-17 Invista North America S.A.R.L. Methods of producing 7-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
CN105026569A (zh) 2012-12-31 2015-11-04 英威达技术有限责任公司 通过丙酮酸和琥珀酸半醛羟醛缩合生产7-碳化学物的方法
CN105073214A (zh) 2012-12-31 2015-11-18 英威达技术有限责任公司 通过甲酯保护的碳链延伸生产6碳化学物的方法
CN105008543A (zh) 2012-12-31 2015-10-28 英威达技术有限责任公司 通过芳香族化合物生产7-碳化学物的方法
EP2938733A2 (fr) 2012-12-31 2015-11-04 Invista North America S.a.r.l. Procédés de production d'agents chimiques par l'allongement de chaîne carbonée protégée par de l'ester méthylique
EP2938736A2 (fr) 2012-12-31 2015-11-04 Invista Technologies S.A R.L. Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b
WO2014105788A2 (fr) 2012-12-31 2014-07-03 Invista North America S.A.R.L. Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de chaîne carbone associé à la synthèse de cyclohexane carboxylate
US20140196904A1 (en) 2013-01-15 2014-07-17 Halliburton Energy Services, Inc. Methods of Controlled Release pH Adjustment for Oilwell Stimulation
WO2015031496A1 (fr) 2013-08-27 2015-03-05 Invista North America S.A.R.L. Procédés et matériels pour la production d'éléments structuraux à cinq atomes de carbone à partir de proline
WO2015036050A1 (fr) 2013-09-16 2015-03-19 Wanted Smiling Gmbh Terminal mobile, serveur, système et procédé pour traiter/échanger de données d'image
CN106795535A (zh) * 2014-06-16 2017-05-31 英威达技术有限责任公司 用于生物合成化合物的方法，试剂和细胞

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361769B1 (en) * 2009-11-16 2013-01-29 U.S. Department Of Energy Regioselective alkane hydroxylation with a mutant CYP153A6 enzyme
US20130183728A1 (en) * 2011-12-16 2013-07-18 Invista North America S.A R.L. METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE
WO2014105793A1 (fr) * 2012-12-31 2014-07-03 Invista North America S.A.R.L. Procédés de production d'agents chimiques à 7 atomes de carbone à partir d'acides gras à longue chaîne par clivage oxydatif

Non-Patent Citations (86)

* Cited by examiner, † Cited by third party
Title
"Manual of Industrial Microbiology and Biotechnology", ASM PRESS
; NIEDER; SHAPIRO, J. BACTERIOL., vol. 122, no. 1, 1975, pages 93 - 98
ANTON; BAIRD: "Polyamides Fibers, Encyclopedia of Polymer Science and Technology", 2001
AURSNES ET AL: "Total synthesis of the lipid mediator PD1(n-3 DPA): Configurational assignments and anti-inflammatory and pro-resolving actions", JOURNAL OF NATURAL PRODUCTS, vol. 77, 27 February 2014 (2014-02-27), pages 910 - 916, XP002742981 *
BARKER ET AL., J. BIOL. CHEM., vol. 262, no. 19, 1987, pages 8994 - 9003
BECKER ET AL., J. BIOTECHNOL.,, vol. 132, 2007, pages 99 - 109
BELLMANN ET AL., MICROBIOLOGY, vol. 147, 2001, pages 1765 - 1774
BOND-WATTS ET AL., BIOCHEMISTRY, vol. 51, 2012, pages 6827 - 6837
BRAMER; STEINBÜCHEL, MICROBIOLOGY, vol. 147, 2001, pages 2203 - 2214
BRIGHAM ET AL.: "Advanced Biofuels and Bioproducts", 2012, pages: 1065 - 1090
BUDDE ET AL., J. BACTERIOL., vol. 192, no. 20, 2010, pages 5319 - 5328
BUGG ET AL., CURRENT OPINION IN BIOTECHNOLOGY, vol. 22, 2011, pages 394 - 400
CANTU ET AL., PROTEIN SCIENCE, vol. 19, 2010, pages 1281 - 1295
CHAYABATRA; LU-KWANG, APPL. ENVIRON. MICROBIOL., vol. 66, no. 2, 2000, pages 493 0 498
CLOMBURG ET AL: "Integrated engineering of beta-oxidation reversal and omega-oxidation pathways for the synthesis of medium chain omega-functionalized carboxylic acids", METABOLIC ENGINEERING, vol. 28, 28 January 2015 (2015-01-28), pages 202 - 212, XP002743043 *
ELKINS; NIKAIDO, J. BACTERIOL., vol. 184, no. 23, 2002, pages 6490 - 6499
FUCHS ET AL., NATURE REVIEWS MICROBIOLOGY, vol. 9, 2011, pages 803 - 816
FUKUI ET AL., J. BACTERIOL., vol. 180, no. 3, 1998, pages 667 - 673
FUNHOFF ET AL., J. BACTERIOL., vol. 188, no. 44, 2006, pages 5220 - 5227
GLOERICH ET AL., FEBS LETTERS, vol. 580, 2006, pages 2092 - 2096
GOBEL ET AL., J. BACTERIOL., vol. 184, no. 1, 2002, pages 216 - 223
GUERRILLOT; VANDECASTEELE, EUR. J. BIOCHEM., vol. 81, 1977, pages 185 - 192
HAYWOOD ET AL., FEMS MžCRO žO OGY LETTERS, vol. 52, 1988, pages 91 - 96
HERMANN ET AL., J. BIOTECHNOL, vol. 104, 2003, pages 155 - 172
HO; WEINER, J. BACTERIOL., vol. 187, no. 3, 2005, pages 1067 - 1073
HUHN ET AL., APPL. MICROBIOL. & BIOTECH., vol. 89, no. 2, pages 327 - 335
IWAKI ET AL., APPL. ENVIRON. MICROBIOL., vol. 65, no. 11, 1999, pages 5158 - 5162
IWAKI ET AL., APPL. ENVIRON. MICROBIOL., vol. 68, no. 11, 2002, pages 5671 - 5684
JARBOE, APPL. MICROBIOL. BIOTECHNOL., vol. 89, no. 2, 2011, pages 249 - 257
JAREMKO; YU, J. BIOTECHNOL., vol. 155, 2011, pages 293 - 298
JING ET AL., BMC BIOCHEMISTRY, vol. 12, no. 44, 2011
K6PKE ET AL., APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 77, no. 15, 2011, pages 5467 - 5475
KAULMANN ET AL., ENZYME AND MICROBIAL TECHNOLOGY, vol. 41, 2007, pages 628 - 637
KIM ET AL., BIOSCI. BIOTECH. BIOCHEM, vol. 58, no. 1, 1994, pages 111 - 116
KIM, THE JOURNAL OF CHEMžSTRY, vol. 239, no. 3, 1964, pages 783 - 786
KOCH ET AL., APPL. ENVIRON. MICROBIOL., vol. 75, no. 2, 2009, pages 337 - 344
LARROY ET AL., BIOCHEM J, vol. 361, 2002, pages 163 - 172
LEE ET AL., APPL. BIOCHEM. BIOTECHNOL., vol. 166, 2012, pages 1801 - 1813
LEE ET AL., BIOTECHNOLOGY PROGRESS, vol. 19, no. 5, 2003, pages 1444 - 1449
LI ET AL., BIODEGRADATION, vol. 22, 2011, pages 1215 - 1225
LIM ET AL., J. BIOSCIENCE AND BIOENGINEERING, vol. 93, no. 6, 2002, pages 543 - 549
LIU ET AL., MICROBIOLOGY, vol. 155, 2009, pages 2078 - 2085
LIU; CHEN, APPL. MICROBIOL. BIOTECHNOL., vol. 76, no. 5, 2007, pages 1153 - 1159
LÓPEZ-SÁNCHEZ ET AL., APPL. ENVIRON. MICROBIOL., vol. 76, no. 1, 2010, pages 110 - 118
LUO ET AL., BIORESOURCE TECHNOLOGY, vol. 103, 2012, pages 1 - 6
LÜTKE-EVERSLOH; STEINBÜCHEL, FEMS MICROBIOLOGY LETTERS, vol. 181, no. 1, 1999, pages 63 - 71
MARTIN; PRATHER, J. BIOTECHNOL., vol. 139, 2009, pages 61 - 67
MEIJNEN ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 90, 2011, pages 885 - 893
NAGGERT ET AL., J. BIOL. CHEM., vol. 266, no. 17, 1991, pages 11044 - 11050
NEYFAKH, ANTIMICROB AGENTS CHEMOTHER, vol. 36, no. 2, 1992, pages 484 - 485
NG ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 38, no. 6, 1994, pages 1345 - 1355
NISHIMAKI ET AL., J. BIOCHEM., vol. 95, 1984, pages 1315 - 1321
NOMURA ET AL., APPL. ENVIRON. MICROBIOL., vol. 71, no. 8, 2005, pages 4297 - 4306
OHASHI ET AL., J. BIOSCIENCE AND BIOENGINEERING, vol. 87, no. 5, 1999, pages 647 - 654
OKUHARA ET AL., AGR. BIOL. CHEM., vol. 35, no. 9, 1971, pages 1376 - 1380
P. F. STANBURY; A. WHITAKER: "Principles of Fermentation Technology", PERGAMON
PALOSAARI; ROGERS, J. BACTERIOL., vol. 170, no. 7, 1988, pages 2971 - 2976
PAPANIKOLAOU ET AL., BIORESOUR. TECHNOL., vol. 99, no. 7, 2008, pages 2419 - 2428
PEREZ-PANTOJA ET AL., FEMS MICROBIOL. REV., vol. 32, 2008, pages 736 - 794
PRYBYLSKI ET AL., ENERGY, SUSTAINABILITY AND SOCIETY, vol. 2, 2012, pages 11
QIU ET AL., PROTEIN SCIENCE, vol. 14, 2005, pages 2087 - 2094
RAJASHEKHARA; WATANABE, FEBS LETTERS, vol. 556, 2004, pages 143 - 147
RAMSAY ET AL., APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 52, no. 1, 1986, pages 152 - 156
SAMSONOVA ET AL., BMC MICROBIOLOGY, vol. 3, no. 2, 2003
SANDERS ET AL., J. LIPID RESEARCH, vol. 46, no. 5, 2005, pages 1001 - 1008
SANDERS ET AL., THE FASEB JOURNAL, vol. 22, no. 6, 2008, pages 2064 - 2071
SATOH ET AL., J. BIOSCIENCE AND BIOENGINEERING, vol. 95, no. 4, 2003, pages 335 - 341
SATOH ET AL., J. BIOSCIENCE AND BžOENGžNEERžNG, vol. 95, no. 4, 2003, pages 335 - 341
SCHELLER ET AL., J. BIOL. CHEM., vol. 269, no. 17, 1994, pages 12779 - 12783
SCHEPS ET AL: "Synthesis of omega-hydroxy dodecanoic acid based on an engineered CYP153A fusion construct", MICROBIAL BIOTECHNOLOGY, vol. 6, 2013, pages 694 - 707, XP055115867 *
SEEDORF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, no. 6, 2008, pages 2128 - 2133
SHEN ET AL., APPL. ENVIRON. MICROBIOL., vol. 77, no. 9, 2011, pages 2905 - 2915
SLATER ET AL., J. BACTERIOL., vol. 180, no. 8, 1998, pages 1979 - 1987
STEINBIICHEL, FEMS MICROBIOLOGY LETTERS, vol. 181, no. 1, 1999, pages 63 - 71
SUZUKI ET AL., BBA - GENERAL SUBJECTS, vol. 882, no. 1, 1986, pages 140 - 142
SUZUKI ET AL., J. ANTIBIOT, vol. 60, no. 6, 2007, pages 380 - 387
SUZUKI ET AL., J. ANTIBIOT., vol. 60, no. 6, 2007, pages 380 - 387
TSENG ET AL., MICROBIAL CELL FACTORIES, vol. 9, 2010, pages 96
VAN BEILEN; FUNHOFF, CURRENT OPINION IN BIOTECHNOLOGY, vol. 16, 2005, pages 308 - 314
VENKITASUBRAMANIAN ET AL., ENZYME AND MICROBIAL TECHNOLOGY, vol. 42, 2008, pages 130 - 137
WEE ET AL., FOOD TECHNOL. BIOTECHNOL, vol. 44, no. 2, 2006, pages 163 - 172
WILSON; BOUWER, JOURNAL OF INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY, vol. 18, no. 2-3, 1997, pages 116 - 130
WOOLRIDGE ET AL., J. BIOL. CHEM., vol. 272, no. 14, 1997, pages 8864 - 8866
YANG ET AL., BIOTECHNOLOGYFOR BIOFUELS, vol. 5, 2012, pages 13
YONAHA ET AL., EUR. J. BIOCHEM., vol. 146, 1985, pages 101 - 106
ZHUANG ET AL., BIOCHEMISTRY, vol. 47, no. 9, 2008, pages 2789 - 2796

Also Published As

Publication number Publication date
BR112016029399A2 (pt) 2017-10-17
EP3155108A1 (fr) 2017-04-19
US9816117B2 (en) 2017-11-14
CN106795536A (zh) 2017-05-31
WO2015195682A1 (fr) 2015-12-23
EP3155109A1 (fr) 2017-04-19
BR112016029365A2 (pt) 2017-10-31
CN106795535A (zh) 2017-05-31
EP3155110A1 (fr) 2017-04-19
US20180002729A1 (en) 2018-01-04
BR112016029391A2 (pt) 2017-10-17
CN106795537A (zh) 2017-05-31
US9738914B2 (en) 2017-08-22
US20150361465A1 (en) 2015-12-17
US20150361466A1 (en) 2015-12-17
US9777302B2 (en) 2017-10-03
US20150361467A1 (en) 2015-12-17
WO2015195678A1 (fr) 2015-12-23

Similar Documents

Publication Publication Date Title
US11268110B2 (en) Methods and materials for the enzymatic conversion of a non-3-enal to azelaic acid
US9790525B2 (en) Methods of producing 7-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
US9920339B2 (en) Methods, reagents and cells for biosynthesizing compounds
US20140193865A1 (en) Methods Of Producing 7-Carbon Chemicals From Long Chain Fatty Acids Via Oxidative Cleavage
US9777302B2 (en) Methods, reagents and cells for biosynthesizing compounds
US20150361458A1 (en) Methods, reagents and cells for biosynthesizing compound
US10947570B2 (en) Materials and methods utilizing biotin producing mutant hosts for the production of 7-carbon chemicals
WO2014105794A2 (fr) Procédés de production d'agents chimiques par l'allongement de chaîne carbonée protégée par de l'ester méthylique
US10988783B2 (en) Methods and materials for producing 7-carbon monomers
US20160201097A1 (en) Materials and Methods of Producing 7-Carbon Monomers
US20160145657A1 (en) Methods and Materials for Producing 7-Carbon Chemicals via a C9 Route
US20170159092A1 (en) Methods and materials for producing 7-carbon monomers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15731806

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016029365

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015731806

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015731806

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112016029365

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161214